Updated on 2024/04/20

写真a

 
USHIKI Takashi
 
Organization
Academic Assembly Institute of Medicine and Dentistry Health Sciences Associate Professor
Faculty of Medicine School of Health Sciences Medical Technology Associate Professor
Title
Associate Professor
▶ display Profile on researchmap
External link

Degree

  • 博士(医学) ( 2010.3   新潟大学 )

Research Interests

  • PMDC05

  • 樹状細胞

  • 造血幹細胞学

  • GVHD

  • PRP

  • 血液内科学

  • 血小板バイオロジー

  • 血液学

  • 造血幹細胞移植

  • 慢性炎症学

  • 輸血学

  • 再生医療

  • 細胞治療

Research Areas

  • Life Science / Nutrition science and health science

  • Life Science / Metabolism and endocrinology

  • Life Science / Hematology and medical oncology  / 輸血・細胞治療学

  • Life Science / Immunology  / 炎症学

  • Life Science / Cell biology

  • Life Science / Sports sciences  / 再生医療

  • Life Science / Biomaterials

▶ display all

Research History (researchmap)

  • 新潟大学医歯学総合病院   輸血・再生・細胞治療センター 兼任

    2022.4

      More details

  • 新潟大学医学部保健学科   血液・腫瘍検査学   准教授

    2022.4

      More details

  • Niigata University   Medical and Dental Hospital

    2019.6 - 2022.3

      More details

  • 新潟大学医歯学総合病院   輸血・再生・細胞治療センター   副部長

    2019.4 - 2022.3

      More details

  • Niigata University   Medical and Dental Hospital   Lecturer

    2019.4 - 2019.5

      More details

  • The Walter and Eliza Hall Institute of Medical Research   Cancer & Haematology Division   Visiting Fellow

    2014.2 - 2014.12

      More details

    Country:Australia

    researchmap

  • 新潟大学医歯学総合病院   生命科学医療センター   副部長(輸血・再生医療担当)

    2013.12 - 2019.3

      More details

  • 新潟大学医歯学総合病院   血液内科 兼任

    2013.11

      More details

  • Niigata University   Medical and Dental Hospital, Bioscience Medical Research Center   Lecturer

    2013.11 - 2019.3

      More details

  • 新潟大学医歯学総合病院   輸血療法委員会   副委員長

    2013 - 2022

      More details

  • The Walter and Eliza Hall Institute of Medical Research   Cancer & Haematology Division   Postdoctral Fellow

    2011.4 - 2013.10

      More details

    Country:Australia

    researchmap

  • Kyoto University   Graduate School of Medicine

    2007.10 - 2009.9

      More details

  • Niigata University   Medical and Dental Hospital, Hematology

    2003.5 - 2011.4

      More details

▶ display all

Research History

  • Niigata University   Medical Technology, School of Health Sciences, Faculty of Medicine   Associate Professor

    2022.4

  • Niigata University   Health Sciences, Institute of Medicine and Dentistry, Academic Assembly   Associate Professor

    2022.4

  • Niigata University   University Medical and Dental Hospital Center For Transfusion and Cell Therapy   Lecturer

    2019.4 - 2022.3

  • Niigata University   University Medical and Dental Hospital Bioscience Medical Research Center   Lecturer

    2013.11 - 2019.3

Education

  • Niigata University   Graduate School of Medical and Dental Sciences

    - 2010.3

      More details

  • Niigata University   Faculty of Medicine   School of Medicine

    - 2003.3

      More details

Professional Memberships

  • 日本自己血輸血学会(自己血輸血責任医師)

    2014 - 2024

      More details

  • THE JAPANESE SOCIETY FOR REGENERATIVE MEDICINE

    2013

      More details

  • 日本造血・免疫細胞療法学会

    2013

      More details

  • 日本がん治療認定医機構(認定医、指導責任者)

    2011

      More details

  • THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY

    2005

      More details

  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

    2004

      More details

  • THE JAPANESE SOCIETY OF HEMATOLOGY

    2004

      More details

▶ display all

Committee Memberships

  • 日本血液学会   評議員  

    2023.9   

      More details

  • 日本輸血・細胞治療学会   細胞治療認定管理師制度 試験委員  

    2023.6   

      More details

  • Frontiers in Immunology   Review Editor (Inflammation Section)  

    2023.2   

      More details

  • 日本血液学会   専門医試験問題作成委員  

    2022.9   

      More details

  • 日本輸血・細胞治療学会   評議員  

    2020.5   

      More details

  • 日本再生医療学会   代議員  

    2018.10   

      More details

    Committee type:Academic society

    researchmap

▶ display all

Studying abroad experiences

  • Walter & Eliza Hall Institute of Medical Research   Postdoctral Fellow

    2011.4 - 2013.10

 

Papers

  • Plasma Gel Matrix as a Promising Carrier of Epigallocatechin Gallate for Regenerative Medicine Reviewed

    Takashi Ushiki, tomoharu mochizuki, Mami, Katsuya Suzuki, Tetsuhiro Tsujino, Taisuke Watanabe, Carlos Fernando Mourão, Tomoyuki Kawase

    Journal of Functional Biomaterials   2024.4

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/jfb15040098

    researchmap

  • Reduced chondroitin sulfate content prevents diabetic neuropathy through TGF-β signaling suppression Reviewed

    Hajime Ishiguro, Takashi Ushiki, Atsuko Honda, Yasuhiro Yoshimatsu, Riuko Ohashi, Shujiro Okuda, Asami Kawasaki, Kaori Cho, Suguru Tamura, Tatsuya Suwabe, Takayuki Katagiri, Yiwei Ling, Atsuhiko Iijima, Tadahisa Mikami, Hiroshi Kitagawa, Akiyoshi Uemura, Kazunori Sango, Masayoshi Masuko, Michihiro Igarashi, Hirohito Sone

    iScience   2024.3

     More details

    Authorship:Corresponding author   Publishing type:Research paper (scientific journal)  

    researchmap

  • Decade-long WT1-specific CTLs induced by WT1 peptide vaccination. Reviewed

    Suwabe T, Shibasaki Y, Tamura S, Katagiri T, Fuse K, Ida-Kurasaki T, Ushiki T, Sone H, Narita M, Masayoshi Masuko

    International journal of hematology   2024.1

     More details

    Publishing type:Research paper (scientific journal)  

    <h4>Introduction</h4>The peptide-based cancer vaccine targeting Wilms' tumor 1 (WT1) is a promising immunotherapeutic strategy for hematological malignancies. It remains unclear how long and to what extent the WT1-specific CD8 + cytotoxic T cell (CTL) persist after WT1 peptide vaccination.<h4>Methods</h4>The WT1 peptide vaccine was administered with written consent to a patient with CML in the chronic phase who did not respond well to imatinib, and the patient was followed for 12 years after vaccination. Immune monitoring was performed by specific amplification of WT1-specific CTLs using a mixed lymphocyte peptide culture. T-cell receptors (TCRs) of amplified WT1-specific CTLs were analyzed using next-generation sequencing. This study was approved by the Institutional Review Board of our institution.<h4>Result</h4>WT1-specific CTLs, which were initially detected during WT1 peptide vaccination, persisted at a frequency of less than 5 cells per 1,000,000 CD8 + T cells for more than 10 years. TCR repertoire analysis confirmed the diversity of WT1-specific CTLs 11 years after vaccination. CTLs exhibited WT1 peptide-specific cytotoxicity in vitro.<h4>Conclusion</h4>The WT1 peptide vaccine induced an immune response that persists for more than 10 years, even after cessation of vaccination in the CML patient.

    DOI: 10.1007/s12185-024-03723-1

    PubMed

    researchmap

  • Elevated IL-1β and Comparable IL-1 Receptor Antagonist Levels Are Characteristic Features of L-PRP in Female College Athletes Compared to Male Professional Soccer Players Reviewed

    Tomoharu Mochizuki, Takashi Ushiki, Katsuya Suzuki, Misato Sato, Hajime Ishiguro, Tatsuya Suwabe, Satoshi Watanabe, mutsuaki edama, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    International Journal of Molecular Sciences   2023.12

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/ijms242417487

    researchmap

  • Metformin-suppressed platelet's function in vitro: Possible relation to delayed or failure of platelet-rich fibrin preparation. Reviewed International journal

    Takashi Uematsu, Hideo Masuki, Masayuki Nakamura, Hideo Kawabata, Yutaka Kitamura, Taisuke Watanabe, Takao Watanabe, Tomoharu Mochizuki, Takashi Ushiki, Tomoyuki Kawase

    Toxicology in vitro : an international journal published in association with BIBRA   93   105692   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Platelet-rich fibrin (PRF) is a popular autologous blood-derived biomaterial that is used in regenerative therapy. Owing to its simple preparation without additional factors, the PRF quality directly reflects the characteristics of individual blood samples. Antiplatelet or anticoagulant drugs can hamper the successful preparation of PRF. We recently observed similar phenomena in metformin-taking type-2 diabetics (T2DM). Thus, we hypothesized that metformin interferes with platelet function, thereby suppressing coagulation. For practical reasons, leukocyte- and platelet-rich plasma was prepared from healthy male donors (n = 9-15, age: 26-80 years) and treated with metformin (1-10 mM) for 24-72 h. Intrinsic and extrinsic coagulation activities were evaluated using prothrombin time (PT) and activated partial thromboplastin time (ATPP). Platelet adhesion and aggregation assays were performed using ADP stimulation. Among the parameters tested, APTT was the most sensitive and was significantly prolonged in the concentration range of 1-10 mM in a time- and concentration-dependent manner. Although obtained from healthy platelets and relatively higher concentrations of metformin, these findings suggest that metformin may induce further dysfunction of platelets to suppress intrinsic coagulation activity in T2DM patients, leading to failure of PRF preparation. This phenomenon may not have a severe impact on clinical diabetology or hematology. However, clinicians using PRF are recommended to be more sensitive to such information to avoid unexpected events in clinical settings.

    DOI: 10.1016/j.tiv.2023.105692

    PubMed

    researchmap

  • Characterization of Leukocyte- and Platelet-Rich Plasma Derived from Female Collage Athletes: A Cross-Sectional Cohort Study Focusing on Growth Factor, Inflammatory Cytokines, and Anti-Inflammatory Cytokine Levels. Reviewed International journal

    Tomoharu Mochizuki, Takashi Ushiki, Katsuya Suzuki, Misato Sato, Hajime Ishiguro, Tatsuya Suwabe, Mutsuaki Edama, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    International journal of molecular sciences   24 ( 17 )   2023.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Platelet-rich plasma (PRP) has been increasingly used in sports medicine owing to its various advantages. The purpose of our project was to standardize the parameters before performing large-scale clinical trials in the near future to precisely evaluate individual PRP quality. To examine the effects of regular exercise on PRP quality, this study focused on young female athletes, who have been relatively less studied. Blood samples were obtained from female college athletes (n = 35) and ordinary healthy adults (n = 30), which were considered as controls, and leukocyte-rich PRP (L-PRP) was prepared manually. Body composition indices were determined using a bathroom weight scale equipped with an impedance meter. Growth factors and cytokines were quantified using ELISA kits. Platelet-derived growth factor-BB (PDGF-BB) and Transforming-growth factors β1 (TGFβ1) levels (per platelet) in L-PRP were significantly lower in female athletes than in controls. In contrast, Interleukin-1β and Interleukin 1 receptor antagonist (IL-1RA) levels (per platelet and L-PRP) in L-PRP were significantly higher in athletes, and this difference was more prominent in IL-1RA. These findings suggest that L-PRP from athletes may facilitate the inflammatory phase of the healing process by regulating the pro-inflammatory and anti-inflammatory balance. These chemical compositions can be adopted as "must-check" parameters to characterize individual PRP preparations prior to clinical trials.

    DOI: 10.3390/ijms241713592

    PubMed

    researchmap

  • Strategic analysis of body composition indices and resting platelet ATP levels in professional soccer players for better platelet-rich plasma therapy. Reviewed International journal

    Takashi Ushiki, Tomoharu Mochizuki, Katsuya Suzuki, Masami Kamimura, Hajime Ishiguro, Tatsuya Suwabe, Satoshi Watanabe, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    Frontiers in bioengineering and biotechnology   11   1255860   2023.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: Autologous platelet-rich plasma (PRP) therapy is ambiguously thought to be more effective in elite athletes than in sedentary patients, although the possible importance of recipient responsiveness remains poorly understood. To address this issue, along with the well-known PRP quality, in this initial study, we evaluated two candidate biomarkers: body composition indices (BCIs), which reflect systemic physical conditions, and resting platelet ATP levels, which reflect platelet energy expenditure and the mass of energy generation units. Methods: In this cross-sectional cohort study, blood samples were collected from male professional soccer players (PSPs) on a local professional team during the off-season and platelet ATP levels were quantified using an ATP luminescence assay kit. BCIs were measured using the body mass impedance method. Age-matched male sedentary participants were used as the controls. Results: Among the BCIs, the body mass index, basal metabolic rate (BMR), and skeletal muscle weight levels were higher in the PSPs than in the controls. The platelet ATP levels in the PSPs group were significantly lower than those in the control group. The correlation between BMR and platelet ATP levels was moderately negative in the control group, but weakly positive in the PSPs group. Conclusion: Owing to regular physical exercise, PSPs had higher BMR levels and lower platelet ATP levels without a significant mutual correlation compared to sedentary controls. This study did not indicate the influence of these biomarkers on the success of PRP therapy but provided evidence for a better understanding of PRP therapy, particularly for elite athletes.

    DOI: 10.3389/fbioe.2023.1255860

    PubMed

    researchmap

  • Genetic manipulation resulting in decreased donor chondroitin sulfate synthesis mitigates hepatic GVHD via suppression of T cell activity. Reviewed International journal

    Suguru Tamura, Hajime Ishiguro, Tatsuya Suwabe, Takayuki Katagiri, Kaori Cho, Kyoko Fuse, Yasuhiko Shibasaki, Tadahisa Mikami, Takero Shindo, Hiroshi Kitagawa, Michihiro Igarashi, Hirohito Sone, Masayoshi Masuko, Takashi Ushiki

    Scientific reports   13 ( 1 )   13098   2023.8

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Donor T cell activation, proliferation, differentiation, and migration are the major steps involved in graft-versus-host disease (GVHD) development following bone marrow transplantation. Chondroitin sulfate (CS) proteoglycan is a major component of the extracellular matrix and causes immune modulation by interacting with cell growth factors and inducing cell adhesion. However, its precise effects on immune function are unclear than those of other proteoglycan families. Thus, we investigated the significance of CS within donor cells in acute GVHD development utilizing CSGalNAc T1-knockout (T1KO) mice. To determine the effects of T1KO, the mice underwent allogenic bone marrow transplantation from major histocompatibility complex-mismatched donors. While transplantation resulted in hepatic GVHD with inflammatory cell infiltration of both CD4+ and CD8+ effector memory T cells, transplantation in T1KO-donors showed milder cell infiltration and improved survival with fewer splenic effector T cells. In vitro T-cell analyses showed that the ratio of effector memory T cells was significantly lower via phorbol myristate acetate/ionomycin stimulation. Moreover, quantitative PCR analyses showed significantly less production of inflammatory cytokines, such as IFN-γ and CCL-2, in splenocytes of T1KO mice. These results suggest that reduction of CS in donor blood cells may suppress the severity of acute GVHD after hematopoietic stem cell transplantation.

    DOI: 10.1038/s41598-023-40367-3

    PubMed

    researchmap

  • Optimized Protocol for Preservation of Human Platelet Samples for Fluorometric Polyphosphate Quantification. Reviewed International journal

    Tomoyuki Kawase, Katsuya Suzuki, Masami Kamimura, Tomoharu Mochizuki, Takashi Ushiki

    Methods and protocols   6 ( 4 )   2023.6

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    Platelet polyphosphate (polyP) can be conveniently quantified by exploiting a recent methodological breakthrough using 4',6-diamidino-2-phenylindole (DAPI). However, the preservation of these biological samples has not yet been standardized. In a preliminary study, potential protocols were screened, while accepted protocols were further tested in this study. Pure-platelet-rich plasma (P-PRP) samples and washed platelet suspensions were prepared using blood obtained from non-smoking healthy male donors and were fixed with ThromboFix for 20-24 h at 4 °C. Mass polyP levels were determined using a fluorometer at wavelengths of 425 and 525 nm. Platelet polyP levels were normalized to platelet counts. Statistical analyses were performed using non-parametric tests. Platelet polyP levels significantly decreased by 20% after 7 days in the platelet suspension maintained under fixed conditions at 4 °C (control). In contrast, the platelet polyP levels in both the P-PRP and washed platelet suspensions were maintained without a significant reduction for up to 6 weeks by removing ThromboFix after fixation and subsequent freezing in pure water at -80 °C. Fluorometric polyP quantification often interferes with the low specificity of DAPI binding and the wavelength used. Our validated protocols will enable long-term preservation and high-throughput polyP quantification and can be applied to relatively large cohort studies.

    DOI: 10.3390/mps6040059

    PubMed

    researchmap

  • コンドロイチン硫酸と糖尿病性神経障害の関連の検討

    石黒 創, 牛木 隆志, 五十嵐 道弘, 曽根 博仁

    新潟県医師会報   R5.4 ( 877 )   12 - 14   2023.4

     More details

  • Hyporesponsiveness against donor's ABO antigens of renal grafts after ABO-incompatible kidney transplantation. Reviewed

    Masayuki Tasaki, Hiroaki Tateno, Takashi Sato, Hisashi Narimatsu, Kazuhide Saito, Yuki Nakagawa, Toshinari Aoki, Masami Kamimura, Takashi Ushiki, Kota Takahashi, Yoshihiko Tomita

    Clinical and experimental nephrology   27 ( 1 )   89 - 95   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: ABO antigens expressed on the red blood cells (RBCs) are not identical to those expressed on the renal endothelial cells. The isohemagglutinin assay employing the RBCs is the gold standard for evaluating anti-ABO antibody (Ab) levels. However, it remains unclear whether the anti-ABO Abs detected by the isohemagglutinin assay after ABO-incompatible (ABOi) kidney transplantations (KTx) that are not associated with antibody-mediated rejection can bind to renal graft endothelial cells. METHODS: Ninety plasma samples were collected from patients with stable graft function after ABO-compatible (ABOc) or ABOi KTx. Anti-ABO Ab titers were examined by both the isohemagglutinin assay and the CD31-ABO microarray, which was developed as a mimic of the ABO antigens expressed on the renal endothelial cells. RESULTS: The antibody titers detected by the isohemagglutinin assay and the CD31-ABO microarray after the ABOc KTx relatively correlated with each other. However, the CD31-ABO microarray results showed low antibody levels against donor blood group antigens after ABOi KTx and did not correlate with the isohemagglutinin assay. In contrast, the antibody levels against non-donor blood group antigens after ABOi KTx were comparable to those after the ABOc KTx. Fourteen patients received graft biopsies, and no antibody-mediated rejection was observed in ABOi KTx recipients, except for two patients who had anti-donor-HLA Abs. CONCLUSION: The present study suggested that the anti-ABO Abs detected by the isohemagglutinin assay after ABOi KTx with stable graft function were hyporeactive to the ABO antigen of graft renal endothelial cells.

    DOI: 10.1007/s10157-022-02280-3

    PubMed

    researchmap

  • The levels of TGFβ1, VEGF, PDGF-BB, and PF4 in platelet-rich plasma of professional soccer players: a cross-sectional pilot study Reviewed

    Tomoharu Mochizuki, Takashi Ushiki, Satoshi Watanabe, Go Omori, Tomoyuki Kawase

    Journal of Orthopaedic Surgery and Research   17 ( 1 )   2022.10

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    <jats:title>Abstract</jats:title><jats:sec>
    <jats:title>Background</jats:title>
    <jats:p>Regenerative therapy using platelet-rich plasma (PRP), a rich source of growth factors, has become popular in orthopedic sports medicine. Elite athletes prefer PRP therapy for their injured muscles and tendons primarily to avoid the possible risks of surgical treatment. However, the clinical effectiveness of PRP therapy in elite athletes compared to that in non-athletes remains unknown. Therefore, to investigate the effectiveness of PRP therapy in professional athletes (pro-athletes), we focused on the quality of PRP preparations and compared the levels of bioactive molecules between pro-athletes and non-athletes.
    </jats:p>
    </jats:sec><jats:sec>
    <jats:title>Methods</jats:title>
    <jats:p>PRP was prepared from healthy, non-smoking male professional soccer players (pro-athletes) (n = 22) and non-athletes (VEGF: n = 34, others: n = 38). The levels of TGFβ1, PDGF-BB, VEGF, and PF4 were determined using ELISA kits. Polyphosphate was probed with 4’,6-diamidino-2-phenylindole and monitored using a fluorometer. The body composition of the donors was determined using a bathroom weighing scale.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Results</jats:title>
    <jats:p>The levels of TGFβ1 and VEGF were significantly lower in pro-athletes than in non-athletes, whereas PF4 levels were significantly higher in pro-athletes. No significant difference was found in PDGF-BB levels between these groups. Biomolecule levels were not correlated with polyphosphate levels.</jats:p>
    </jats:sec><jats:sec>
    <jats:title>Conclusion</jats:title>
    <jats:p>TGFβ1, VEGF, and PDGF-BB levels in pro-athletes were not higher than those in non-athletes. These findings suggest that growth factor levels in PRP may not be a predominant determinant of the clinical effectiveness of PRP therapy in pro-athletes. Increased PF4 levels in pro-athletes suggest an immunological function of PRP that may positively influence tissue regeneration.</jats:p>
    </jats:sec>

    DOI: 10.1186/s13018-022-03362-4

    researchmap

  • Hyporesponsiveness against donor’s ABO antigens of renal grafts after ABO-incompatible kidney transplantation Reviewed

    Masayuki Tasaki, Hiroaki Tateno, Takashi Sato, Hisashi Narimatsu, Kazuhide Saito, Yuki Nakagawa, Toshinari Aoki, Masami Kamimura, Takashi Ushiki, Kota Takahashi, Yoshihiko Tomita

    Clinical and Experimental Nephrology   2022.9

     More details

  • Modulation of ATP Production Influences Inorganic Polyphosphate Levels in Non-Athletes' Platelets at the Resting State. Reviewed International journal

    Takashi Ushiki, Tomoharu Mochizuki, Katsuya Suzuki, Masami Kamimura, Hajime Ishiguro, Tatsuya Suwabe, Tomoyuki Kawase

    International journal of molecular sciences   23 ( 19 )   2022.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Platelets produce inorganic polyphosphate (polyP) upon activation to stimulate blood coagulation. Some researchers have linked polyP metabolism to ATP production, although the metabolic linkage is yet to be elucidated. We found evidence for this possibility in our previous study on professional athletes (versus non-athletes), and proposed that the regulatory mechanism might be different for these two groups. To explore this aspect further, we investigated the effects of modulated ATP production on polyP levels. Blood samples were obtained from Japanese healthy, non-athletes in the presence of acid-citrate-dextrose. The platelets in the plasma were treated with oligomycin, rotenone, and GlutaMAX to modulate ATP production. PolyP level was quantified fluorometrically and visualized using 4',6-diamidino-2-phenylindole. Correlations between polyP and ATP or NADH were then calculated. Contrary to the hypothesis, inhibitors of ATP production increased polyP levels, whereas amino acid supplementation produced the opposite effect. In general, however, polyP levels were positively correlated with ATP levels and negatively correlated with NADH levels. Since platelets are metabolically active, they exhibit high levels of ATP turnover rate. Therefore, these findings suggest that ATP may be involved in polyP production in the resting platelets of non-athletes.

    DOI: 10.3390/ijms231911293

    PubMed

    researchmap

  • Platelet polyphosphate and energy metabolism in professional male athletes (soccer players): A cross‐sectional pilot study Reviewed International journal

    Takashi Ushiki, Tomoharu Mochizuki, Katsuya Suzuki, Masami Kamimura, Hajime Ishiguro, Satoshi Watanabe, Go Omori, Noriaki Yamamoto, Tomoyuki Kawase

    Physiological Reports   10 ( 15 )   e15409   2022.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Human platelet polyphosphate (polyP) is a multifunctional molecule; however, its functions are not yet fully understood. A recent study demonstrated that similar to skeletal muscle, polyP is involved in energy metabolism in platelets, which suggests that well-trained athletes may exhibit elevated platelet polyP levels for energy storage. To test this hypothesis, we quantified platelet polyP along with NADH, a component involved in ATP production in non-trained and well-trained male Japanese participants of the same generation. Washed platelets were prepared from the venous blood of young, healthy, non-athletes, and professional soccer players (pro-athletes). NADH and polyP levels were spectrophotometrically determined using tetrazolium reduction and fluorometrically determined using 4',6-diamidino-2-phenylindole at the excitation/emission wavelengths of 425/525 nm. Body weight and impedances were measured simultaneously. Statistical analyses were performed using the Mann-Whitney U test and Spearman correlation coefficient. Although basal metabolic rate levels were significantly higher, platelet polyP levels were significantly lower in pro-athletes than in that in non-athletes. No significant differences were detected in other body compositions or platelet indices between the two groups. The pro-athlete group showed a moderate, nearly significant correlation (R = 0.439; p = 0.0512) between platelet polyP and NADH levels. Taken together with the weak correlation data between polyP and body mass index, it is suggested that platelet polyP levels may be influenced by platelet and body energy metabolic activity. Further biochemical studies are needed to elucidate this mechanism.

    DOI: 10.14814/phy2.15409

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.14814/phy2.15409

  • A Novel Method of CD31-Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation Reviewed

    Masayuki Tasaki, Hiroaki Tateno, Takashi Sato, Azusa Tomioka, Hiroyuki Kaji, Hisashi Narimatsu, Kazuhide Saito, Yuki Nakagawa, Toshinari Aoki, Masami Kamimura, Takashi Ushiki, Manabu Okada, Yuko Miwa, Kiyohiko Hotta, Yutaka Yoshida, Kota Takahashi, Yoshihiko Tomita

    Transplant International   35   2022.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Frontiers Media SA  

    Isohemagglutinin assays employing red blood cells (RBCs) are the most common assays used to measure antibody titer in ABO-incompatible kidney transplantation (ABOi KTx). However, ABO antigens expressed on RBCs are not identical to those of kidney and antibody titers do not always correlate with clinical outcome. We previously reported that CD31 was the main protein linked to ABO antigens on kidney endothelial cells (KECs), which was different from those on RBCs. We developed a new method to measure antibody titer using a microarray of recombinant CD31 (rCD31) linked to ABO antigens (CD31-ABO microarray). Mass spectrometry analysis suggested that rCD31 and native CD31 purified from human kidney had similar ABO glycan. To confirm clinical use of CD31-ABO microarray, a total of 252 plasma samples including volunteers, hemodialysis patients, and transplant recipients were examined. In transplant recipients, any initial IgG or IgM antibody intensity &amp;gt;30,000 against the donor blood type in the CD31-ABO microarray showed higher sensitivity, specificity, positive predictive value, and negative predictive value of AABMR, compared to isohemagglutinin assays. Use of a CD31-ABO microarray to determine antibody titer specifically against ABO antigens expressed on KECs will contribute to precisely predicting AABMR or preventing over immunosuppression following ABOi KTx.

    DOI: 10.3389/ti.2022.10248

    researchmap

  • Altered Microbiota by a High-Fat Diet Accelerates Lethal Myeloid Hematopoiesis Associated with Systemic Socs3 Deficiency Reviewed

    Kaori Cho, Takashi Ushiki, Hajime Ishiguro, Suguru Tamura, Masaya Araki, Tatsuya Suwabe, Takayuki Katagiri, Mari Watanabe, Yoko Fujimoto, Riuko Ohashi, Yoichi Ajioka, Ippei Shimizu, Shujiro Okuda, Masayoshi Masuko, Yoshimi Nakagawa, Hideyo Hirai, Warren S. Alexander, Hitoshi Shimano, Hirohito Sone

    iScience   103117   2021.9

     More details

    Authorship:Corresponding author   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.isci.2021.103117

    researchmap

  • Osteoclastogenic Potential of Tissue-Engineered Periosteal Sheet: Effects of Culture Media on the Ability to Recruit Osteoclast Precursors. Reviewed International journal

    Kohya Uematsu, Takashi Ushiki, Hajime Ishiguro, Riuko Ohashi, Suguru Tamura, Mari Watanabe, Yoko Fujimoto, Masaki Nagata, Yoichi Ajioka, Tomoyuki Kawase

    International journal of molecular sciences   22 ( 4 )   2021.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Cell culture media influence the characteristics of human osteogenic periosteal sheets. We have previously found that a stem cell medium facilitates growth and collagen matrix formation in vitro and osteogenesis in vivo. However, it has not yet been demonstrated which culture medium is superior for osteoclastogenesis, a prerequisite for reconstruction of normal bone metabolic basis. To address this question, we compared chemotaxis and osteoclastogenesis in tissue-engineered periosteal sheets (TPSs) prepared with two types of culture media. Periosteal tissues obtained from adult volunteers were expanded with the conventional Medium 199 or with the stem cell medium, MesenPRO. Hematopoietic enhanced-green-fluorescent-protein (EGFP)-nude mice were prepared by γ-irradiation of Balb/c nu/nu mice and subsequent transplantation of bone marrow cells from CAG-EGFP C57BL/6 mice. TPSs were implanted subcutaneously into the chimeric mice and retrieved after intervals for immunohistopathological examination. EGFP+ cells were similarly recruited to the implantation site in both the TPSs prepared, whereas the distribution of CD11b+ cells was significantly lower in the TPS prepared with the stem cell medium. Instead, osteoclastogenesis was higher in the TPS prepared with the stem cell medium than in the one prepared with the conventional medium. These findings suggest that the stem cell medium is preferable for the preparation of more functional TPSs.

    DOI: 10.3390/ijms22042169

    PubMed

    researchmap

  • Distinct effects of chondroitin sulfate on hematopoietic cells and the stromal microenvironment in bone marrow hematopoiesis. Reviewed International journal

    Takayuki Katagiri, Shun Uemura, Takashi Ushiki, Yaeko Nakajima-Takagi, Motohiko Oshima, Tadahisa Mikami, Asami Kawasaki, Hajime Ishiguro, Tomoyuki Tanaka, Hirohito Sone, Hiroshi Kitagawa, Michihiro Igarashi, Atsushi Iwama, Masayoshi Masuko

    Experimental hematology   96   52 - 62   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The bone marrow (BM) microenvironment, known as the BM niche, regulates hematopoiesis but is also affected by the interactions with hematopoietic cells. Recent evidence indicates that the extracellular matrix components are involved in these interactions. Chondroitin sulfate (CS), a glycosaminoglycan, is a major component of the extracellular matrix; however, it is not known whether CS has a physiological role in hematopoiesis. Here, we analyzed the functions of CS in hematopoietic and niche cells. CSGalNAcT1, which encodes CS N-acetylgalactosaminyltransferase-1 (T1), a key enzyme for CS biosynthesis, was highly expressed in hematopoietic stem and progenitor cells (HSPCs) and endothelial cells, but not in mesenchymal stromal cells (MSCs) in BM. In T1 knockout (T1KO) mice, a greater number of HSPCs existed compared to the wild type (WT), but HSPCs from T1KO mice showed significantly impaired repopulation in WT recipient mice upon serial transplantation. RNA sequence analysis revealed the activation of IFN-α/β signaling and endoplasmic reticulum stress in T1KO HSPCs. In contrast, the number of WT HSPCs repopulated in T1KO recipient mice was larger than that in WT recipient mice after serial transplantation, indicating that the T1KO niche supports repopulation of HSPCs better than the WT niche. There was no obvious difference in the distribution of vasculature and MSCs between WT and T1KO BM, suggesting that CS loss alters vascular niche functions without affecting its structure. Our results revealed distinct roles of CS in hematopoietic cells and BM niche, indicating that crosstalk between these components is important to maintain homeostasis in BM.

    DOI: 10.1016/j.exphem.2021.02.003

    PubMed

    researchmap

  • Immunoglobulin therapy for successful management of prolonged, recurrent jaundice in a young adult male with combined immunodeficiency. Reviewed

    Chiyumi Oda, Atsunori Tsuchiya, Atsushi Kimura, Kentaro Tominaga, Kazunao Hayashi, Takashi Ushiki, Hajime Umezu, Shuji Terai

    Clinical journal of gastroenterology   14 ( 4 )   1197 - 1201   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Jaundice may be persistent in drug-induced liver injury associated with vanishing bile duct syndrome. However, recurrent jaundice is atypical, following bile flow restoration. Here, we report a 28-year-old man with prolonged, recurrent jaundice (more than 300 days) and combined immunodeficiency (CID) of B-cells, T-cells, and natural killer (NK) cells. Hypogammaglobulinemia was observed throughout his hospitalization, and peripheral blood flow cytometry detected a few B-cells (2% of CD19 + cells and 2% of CD20 + cells). We further detected the dysfunction of T-cells and NK cells. Based on these findings, CID was diagnosed. We presumed that hypogammaglobulinemia was related to the jaundice. After regular injections of intravenous immunoglobulin (IVIG), the stool color gradually turned brown. However, the color returned to white as IgG levels decreased. The brown-to-white stool pattern was repeated with another IVIG administration, suggesting that the patient's serum immunoglobulin levels were related to the jaundice. On follow-up, IVIG was performed every two to three weeks, and his total bilirubin improved gradually. Immunoglobulin replacement therapy could be one of the treatment choices for jaundice with CID.

    DOI: 10.1007/s12328-021-01347-0

    PubMed

    researchmap

  • WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS. Reviewed

    Tatsuya Suwabe, Yasuhiko Shibasaki, Hiroyuki Sato, Suguru Tamura, Takayuki Katagiri, Hiroki Nemoto, Takuya Kasami, Takashi Kozakai, Ayako Nanba, Toshiki Kitajima, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

    International journal of hematology   113 ( 5 )   723 - 734   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Wilms' tumor 1 (WT1) is a tumor-associated antigen and immunotherapy target in myelodysplastic syndrome (MDS). Further information is needed on the characteristics of WT1-specific CD8 + T cells to develop immunotherapeutic strategies for MDS. To clarify the frequency, distribution, and phenotype of WT1-specific CD8 + T cells, which occur innately in MDS patients, we analyzed paired peripheral blood (PB) and bone marrow (BM) samples from 39 patients with MDS or acute myeloid leukemia with myelodysplasia-related changes. The median frequency of WT1 tetramer-binding CD8 + T cells in the CD8 + T cell population was 0.11% in PB and 0.18% in BM. A further tetramer assay combined with mixed lymphocyte peptide culture (MLPC assay) was used to detect functional WT1-specific CD8 + T cells that could respond to the WT1 peptide. Functional WT1-specific CD8 + T cells were detected in BM in 61% of patients, which was significantly higher than in PB (23%, p = 0.001). The frequency of these cells estimated by the MLPC assay was tenfold higher in BM than in PB. The majority of WT1 tetramer-binding CD8 + T cells in BM had a unique phenotype with co-expression of CD39 and CXCR4. These findings will facilitate the development of novel immunotherapeutic strategies for MDS.

    DOI: 10.1007/s12185-021-03083-0

    PubMed

    researchmap

  • Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. Reviewed International journal

    Kyoko Fuse, Shun Uemura, Suguru Tamura, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tatsuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Cancer medicine   8 ( 11 )   5058 - 5067   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEMATOLOGY  

    Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for high-risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient-based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ-statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision-making process in the diversified allo-HSCT field and be useful for preventing the relapse of leukemia.

    DOI: 10.1002/cam4.2401

    Web of Science

    PubMed

    researchmap

  • Detecting irregular antibodies using a micro typing system in infants under four months of age Reviewed

    Masami Kamimura, Toshinari Aoki, Misato Sato, Momo Watanabe, Naoe Ohki, Ayano Kawai, Masayoshi Masuko, Koh Nakata, Takashi Ushiki

    Japanese Journal of Transfusion and Cell Therapy   65 ( 3 )   562 - 567   2019.6

     More details

    Authorship:Last author, Corresponding author   Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    生後4ヵ月未満児は得られる採血量が少ないことから、自動輸血検査装置や試験管法では不規則抗体検査が困難である。このため、当院では検体量が試験管法の約1/4と少量の検体で検査可能なMicro Typing Systemを採用している。2007年1月から2016年12月までの10年間においてMicro Typing Systemでは不規則抗体検査依頼のあった生後4ヵ月未満児554件中、552件(99.6%)で検査可能であった。症例の内訳では55.4%が先天性心疾患の症例であった。また、検査可能であった552件中、不規則抗体が16件(2.9%)で陽性判定であった。そのうちの14件は母親からの移行抗体、1件は移行抗体が疑われた抗E、1件は自然抗体と考えられるIgM型の抗Mであった。さらに実際に358件に赤血球輸血が実施され、その内230件(64.2%)に輸血後の不規則抗体検査が行われたが、輸血後に生後4ヵ月未満児が不規則抗体を産生した症例は認められなかった。ほぼ全例に不規則抗体スクリーニング検査を可能とするMicro Typing Systemは乳児への輸血療法の安全性確保の観点において有用である。(著者抄録)

    researchmap

  • Rh<sub>null</sub> phenotype caused by a novel RHAG mutation, c.945+1G>A, in the Japanese population. Reviewed International journal

    Ushiki T, Tsuneyama H, Masuko M, Kozakai T, Kasami T, Tanaka T, Uchikawa M, Kitajima T, Kasai E, Komata T, Katagiri T, Kamimura M, Sato K, Fuse I, Ogasawara K, Nakata K

    Transfusion   59 ( 8 )   2519 - 2522   2019.4

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The Rh complex contributes to cell membrane structural integrity of erythrocytes. Rhnull syndrome is characterized by the absence of the Rh antigen on the erythrocyte membrane, resulting in chronic hemolytic anemia. We recently came across 3 Rhnull phenotype probands within two families with the same novel RHAG mutation in the Japanese population. MATERIALS AND METHODS: Detailed Rh phenotyping by hemagglutination was performed using monoclonal and polyclonal anti-D, -C, -c, -E, and -e; monoclonal and polyclonal anti-Rh17 antibodies; and polyclonal anti-Rh29 antibodies. RHAG mRNA transcripts were analyzed by reverse transcription-polymerase chain reaction, and the mutation was verified by genomic sequencing. RESULTS: The genomic region spanning exon 6 contained a G > A transition in the invariant GT motif of the 5' donor splice-site of Intron 6 (c.945+1G>A). The Rhnull phenotype was caused by an autosomal recessive mutation in Probands 1 and 2, determined by family history. Regarding clinical features, the degree of hemolysis varied slightly between these individuals, with Proband 3 displaying acute hemolytic anemia with an infection. While no standard therapy has been established, the condition of the patient in this study improved with conservative treatment, including hydration and antibiotics. CONCLUSION: The mechanisms of hemolysis due to the Rhnull phenotype can vary, but our findings indicate that acute hemolytic crisis caused by the Rhnull syndrome could be associated with infection.

    DOI: 10.1111/trf.15312

    PubMed

    researchmap

  • Platelet-Rich Fibrin Extract: A Promising Fetal Bovine Serum Alternative in Explant Cultures of Human Periosteal Sheets for Regenerative Therapy. Reviewed

    Kawase T, Nagata M, Okuda K, Ushiki T, Fujimoto Y, Watanabe M, Ito A, Nakata K

    International journal of molecular sciences   20 ( 5 )   2019.2

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3390/ijms20051053

    PubMed

    researchmap

  • 同種造血細胞移植における移植前リスク評価に用いられるGlasgow予後予測スコアの改良(Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation)

    Shibasaki Yasuhiko, Suwabe Tatsuya, Katagiri Takayuki, Tanaka Tomoyuki, Ushiki Takashi, Fuse Kyoko, Sato Naoko, Yano Toshio, Kuroha Takashi, Hashimoto Shigeo, Narita Miwako, Furukawa Tatsuo, Sone Hirohito, Masuko Masayoshi

    International Journal of Hematology   108 ( 3 )   282 - 289   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    同種造血細胞移植(HCT)の移植前リスク評価に用いられるGlasgow予後予測スコア(GPS)に改良を加え、その有用性について検討した。同種HCTを施行された血液疾患患者205例(中央値46歳)を対象とした。HCT特異的GPS(HCT-GPS)の評価に際して、CRP上昇(1mg/dL超)、低アルブミン血症(3.5g/dL未満)の両者を満たす場合は2点、いずれかを呈する場合は1点、いずれも認めない場合は0点とし、さらに血清中フェリチン1000ng/mL超を呈する場合には+1点とした。検討の結果、移植前の血清フェリチン中央値は954ng/mL、アルブミン中央値は4.1g/dL、CRP中央値は0.14mg/dLであり、HCT-GPSスコアは0点が95例、1点が75例、2点が19例、3点が16例であった。一方、オリジナルのGPSスコアでは0点が158例、1点が28例、2点が19例であった。C統計量分析では非再燃死亡率(NRM)と全生存率(OS)はHCT-GPSスコアの方がGPSスコアより高値であったが有意差は認められなかった。一方、net reclassification indexesとintegrated discrimination improvementを用いた解析では有意差がみられた。また、多変量解析ではHCT-GPSスコアの1点増分はOSとNRMの不良を示す独立予測因子であることが示された。今回作成したHCT-GPSスコアは同種HCT後の早期合併症の予測に有用なツールに成りうると思われた。

    researchmap

    Other Link: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J04671&link_issn=&doc_id=20181129310007&doc_link_id=10.1007%2Fs12185-018-2463-x&url=https%3A%2F%2Fdoi.org%2F10.1007%2Fs12185-018-2463-x&type=Crossref&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00002_2.gif

  • Heterogeneity of intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological malignancies Reviewed

    Hironori Kobayashi, Norihiko Yoshimura, Shun Uemura, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    Leukemia Research   70   41 - 44   2018.7

     More details

    Language:English   Publisher:Elsevier Ltd  

    DOI: 10.1016/j.leukres.2018.05.005

    Scopus

    PubMed

    researchmap

  • Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation Reviewed

    Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Miwako Narita, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    International Journal of Hematology   108 ( 3 )   1 - 8   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Tokyo  

    The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is a widely used tool for pre-transplant risk assessment. Allogeneic hematopoietic cell transplantation (HCT) is performed on patients with diverse backgrounds, highlighting the need for other predictors to complement the HCT-CI and support bedside decision-making. There is a strong body of evidence supporting the use of pre-transplant serum ferritin (SF) in risk assessments of allogeneic HCT. We additionally found that the Glasgow Prognostic Score (GPS), which assesses inflammatory biomarkers and predicts survival of patients with solid organ malignancies, is a useful predictive marker for overall survival (OS) and non-relapse mortality (NRM) in allogeneic HCT, independent of HCT-CI and SF. In this study, we refined the GPS by adding pre-transplant SF to improve its prognostic ability and enable better stratification
    we call this revised index the HCT-specific revised Glasgow Prognostic Score (HCT-GPS). We observed that the HCT-GPS more accurately predicted NRM and early-term OS than the GPS. Moreover, the HCT-GPS provides an independent prognostic factor adjusted for the HCT-CI and disease status, and stratifies patients into four risk groups by OS and NRM. Thus, the HCT-GPS is a useful index for predicting early-term complications after allogeneic HCT in patients with hematopoietic diseases.

    DOI: 10.1007/s12185-018-2463-x

    Scopus

    PubMed

    researchmap

  • The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation Reviewed

    Yasuhiko Shibasaki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Hironori Kobayashi, Kyoko Fuse, Takashi Ushiki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Miwako Narita, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    CLINICAL TRANSPLANTATION   31 ( 11 )   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY  

    Evaluation methods, such as scoring systems for predicting complications in advance, are necessary for determining the adaptation of allogeneic hematopoietic cell transplantation (HCT) and selecting appropriate conditioning regimens. The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), which is based on functions of main organs, is a useful tool for pre-transplant risk assessments and has been widely applied in determining treatment strategies for patients with hematological diseases. However, as allogeneic HCT is performed on patients with diverse backgrounds, another factor, which reinforces the HCT-CI, is required to evaluate pre-transplant risk assessments. The Glasgow Prognostic Score (GPS), which assesses the combined C-reactive protein and albumin, was reported to predict survival of patients with solid-organ malignancies independently of receiving chemo/radiotherapy and stages of cancer. In this study, we applied the GPS for pre-transplant risk assessments for allogeneic HCT. The GPS successfully stratified the patients into three risk groups of overall survival (OS) and non-relapse mortality (NRM). Moreover, the GPS could predict outcomes independently of the HCT-CI for OS and NRM in multivariate analysis. The GPS is considered to be a useful tool and reinforces the HCT-CI for determining adaptation of allogeneic HCT for patients with hematopoietic neoplasms.

    DOI: 10.1111/ctr.13103

    Web of Science

    PubMed

    researchmap

  • Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome A case report and literature review Reviewed

    Takayuki Katagiri, Takashi Ushiki, Masayoshi Masuko, Tomoyuki Tanaka, Shukuko Miyakoshi, Kyoko Fuse, Yasuhiko Shibasaki, Jun Takizawa, Sadao Aoki, Hirohito Sone

    MEDICINE   96 ( 36 )   e7975   2017.9

     More details

    Authorship:Corresponding author   Language:English   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Rationale: Myeloid sarcoma (MS) and leukemia cutis (LC) are extramedullary tumors comprising myeloid blasts. They can occur de novo or concurrently with hematological disorders, usually acute myeloid leukemia (AML). AML chemotherapy is generally the initial therapy for MS and LC, and hematopoietic stem cell transplantation (HSCT) can be considered as additional therapy. However, treatment for older patients who are unable to continue intensive chemotherapy is not currently standardized.
    Patientconcerns: A 71-year-old Japanese woman was diagnosed with multiple MSs associated with myelodysplastic syndrome (MDS), using bone marrow aspiration and lymph node biopsy.
    Diagnoses: Additionally, LC was diagnosed by skin biopsy. Extramedullary MS and LC lesions were formed by massive infiltration of myeloblastic cells.
    Interventions: Twenty courses of 5-azacytidine (5-Aza) were administrated as maintenance therapy after induction therapy with daunorubicin and cytarabine.
    Outcomes: Myeloblasts decreased in the bone marrow and the LC disappeared after induction therapy. The MSs completely disappeared, except for the palatine tonsil lesion, after 5-Aza maintenance therapy. 5-Aza treatment provided long-term partial response for more than 21 months.
    Lessons: 5-Aza was well tolerated and may be a good option for the treatment of MS and LC associated with MDS, especially in older patients who cannot receive HSCT.

    DOI: 10.1097/MD.0000000000007975

    Web of Science

    PubMed

    researchmap

  • Peripheral T-cell lymphoma, not otherwise specified: a retrospective single-center analysis. Reviewed

    Suzuki T, Kawamoto K, Tamura S, Uemura S, Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y, Moriyama M, Masuko M, Narita M, Sone H, Aoki S, Nakamura N, Oshima K, Takizawa J

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 8 )   905 - 911   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    We retrospectively analyzed clinical and pathological features, treatments, and prognoses in 28 patients with newly diagnosed peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) in Niigata University Medical and Dental Hospital. Of them, 16 were males and 12 were females, and their median age was 62.5 (range, 26-88) years. The International Prognostic Index was high-intermediate/high in 68% of patients. Twelve patients were treated with CHOP/THP-COP and nine with third-generation chemotherapy regimens. At a median follow-up period of 30 (range: 1-164) months, the 2-year overall survival and progression-free survival rates were 61% and 44%, respectively. Further investigation of novel agents for treating PTCL-NOS is warranted.

    DOI: 10.11406/rinketsu.58.905

    PubMed

    researchmap

  • Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy. Reviewed

    Suwabe T, Shibasaki Y, Kaihatsu A, Katagiri T, Miyakoshi S, Fuse K, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 1 )   32 - 36   2017

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 62-year-old man with CHOP refractory adult T-cell leukemia/lymphoma (ATLL) received anti-CC chemokine receptor 4 antibody (mogamulizumab) combined with CHOP and achieved complete remission. At 71 days after the final administration of mogamulizumab, he received umbilical cord blood transplantation (CBT) using reduced intensity conditioning. Umbilical cord blood engraftment was confirmed on day16. Grade II acute graft-versus-host disease (GVHD) was diagnosed on day60 and was controlled by administration of methylprednisolone. There was no evidence of relapse at 9 months after CBT. Ratios of regulatory T cells in CD4 positive T cells were remarkably low during all of these periods. Since mogamulizumab reduces regulatory T cells, the frequency and severity of acute GVHD were reported to be increased in patients administered mogamulizumab before allogenic stem cell transplantation. Further experiences are needed for selecting optimal donor sources, the portability period and GVHD prophylaxis for patients using mogamulizumab before allogeneic stem cell transplantation.

    DOI: 10.11406/rinketsu.58.32

    PubMed

    researchmap

  • [Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity]. Reviewed

    Tanaka T, Kozakai T, Kitajima T, Fuse K, Kobayashi H, Ushiki T, Shibazaki Y, Moriyama M, Takizawa J, Sone H, Fuse I, Masuko M

    [Rinsho ketsueki] The Japanese journal of clinical hematology   58 ( 12 )   2402 - 2405   2017

     More details

    Language:Japanese   Publisher:The Japanese Society of Hematology  

    <p>A 75-year-old woman suffered a cat bite 10 months after myelodysplastic syndrome (MDS) diagnosis. She visited our hospital because the internal bleeding of the wound did not improve. Although the wound was treated, the bleeding did not stop. She was hospitalized for emergency medical treatment because the bleeding volume exceeded 200 m<i>l</i>. Although her platelet count was normal, the platelet function test showed a decrease in collagen and arachidonic acid aggregation. After platelet transfusion, her bleeding stopped. Patients with MDS may potentially have platelet dysfunction. In the case of bleeding without thrombocytopenia, a platelet function test should be performed and treatment intervention, such as platelet transfusion, should be considered.</p>

    DOI: 10.11406/rinketsu.58.2402

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2018121562

  • Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells Reviewed

    Takashi Ushiki, Nicholas D. Huntington, Stefan P. Glaser, Hiu Kiu, Angela Georgiou, Jian-Guo Zhang, Donald Metcalf, Nicos A. Nicola, Andrew W. Roberts, Warren S. Alexander

    PLOS ONE   11 ( 9 )   e0162111   2016.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:PUBLIC LIBRARY SCIENCE  

    The Suppressors of Cytokine Signalling (SOCS) proteins are negative regulators of cytokine signalling required to prevent excess cellular responses. SOCS1 and SOCS3 are essential to prevent inflammatory disease, SOCS1 by attenuating responses to IFN gamma and gamma-common (gamma c) cytokines, and SOCS3 via regulation of G-CSF and IL-6 signalling. SOCS1 and SOCS3 show significant sequence homology and are the only SOCS proteins to possess a KIR domain. The possibility of overlapping or redundant functions was investigated in inflammatory disease via generation of mice lacking both SOCS1 and SOCS3 in hematopoietic cells. Loss of SOCS3 significantly accelerated the pathology and inflammatory disease characteristic of SOCS1 deficiency. We propose a model in which SOCS1 and SOCS3 operate independently to control specific cytokine responses and together modulate the proliferation and activation of lymphoid and myeloid cells to prevent rapid inflammatory disease.

    DOI: 10.1371/journal.pone.0162111

    Web of Science

    PubMed

    researchmap

  • CIS is a potent checkpoint in NK cell-mediated tumor immunity Reviewed

    Rebecca B. Delconte, Tatiana B. Kolesnik, Laura F. Dagley, Jai Rautela, Wei Shi, Eva M. Putz, Kimberley Stannard, Jian-Guo Zhang, Charis Teh, Matt Firth, Takashi Ushiki, Christopher E. Andoniou, Mariapia A. Degli-Esposti, Phillip P. Sharp, Caroline E. Sanvitale, Giuseppe Infusini, Nicholas P. D. Liau, Edmond M. Linossi, Christopher J. Burns, Sebastian Carotta, Daniel H. D. Gray, Cyril Seillet, Dana S. Hutchinson, Gabrielle T. Belz, Andrew I. Webb, Warren S. Alexander, Shawn S. Li, Alex N. Bullock, Jeffery J. Babon, Mark J. Smyth, Sandra E. Nicholson, Nicholas D. Huntington

    NATURE IMMUNOLOGY   17 ( 7 )   816 - +   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    The detection of aberrant cells by natural killer (NK) cells is controlled by the integration of signals from activating and inhibitory ligands and from cytokines such as IL-15. We identified cytokine-inducible SH2-containing protein (CIS, encoded by Cish) as a critical negative regulator of IL-15 signaling in NK cells. Cish was rapidly induced in response to IL-15, and deletion of Cish rendered NK cells hypersensitive to IL-15, as evidenced by enhanced proliferation, survival, IFN-gamma production and cytotoxicity toward tumors. This was associated with increased JAK-STAT signaling in NK cells in which Cish was deleted. Correspondingly, CIS interacted with the tyrosine kinase JAK1, inhibiting its enzymatic activity and targeting JAK for proteasomal degradation. Cish(-/-) mice were resistant to melanoma, prostate and breast cancer metastasis in vivo, and this was intrinsic to NK cell activity. Our data uncover a potent intracellular checkpoint in NK cell-mediated tumor immunity and suggest possibilities for new cancer immunotherapies directed at blocking CIS function.

    DOI: 10.1038/ni.3470

    Web of Science

    PubMed

    researchmap

  • The Dinakara equation for adjusting DLCO for hemoglobin in the HCT-CI is superior to the Cotes equation for predicting high-risk patients in allogeneic hematopoietic stem cell transplantation. Reviewed International journal

    Yasuhiko Shibasaki, Takayuki Katagiri, Hironori Kobayashi, Takashi Ushiki, Miwako Narita, Hirohito Sone, Tatsuo Furukawa, Masayoshi Masuko

    American journal of hematology   91 ( 5 )   E296 - E297   2016.5

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    DOI: 10.1002/ajh.24318

    Web of Science

    PubMed

    researchmap

  • The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15 Reviewed

    Rebecca B. Delconte, Wei Shi, Priyanka Sathe, Takashi Ushiki, Cyril Seillet, Martina Minnich, Tatiana B. Kolesnik, Lucille C. Rankin, Lisa A. Mielke, Jian-Guo Zhang, Meinrad Busslinger, Mark J. Smyth, Dana S. Hutchinson, Stephen L. Nutt, Sandra E. Nicholson, Warren S. Alexander, Lynn M. Corcoran, Eric Vivier, Gabrielle T. Belz, Sebastian Carotta, Nicholas D. Huntington

    IMMUNITY   44 ( 1 )   103 - 115   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CELL PRESS  

    The inhibitor of DNA binding 2 (Id2) is essential for natural killer (NK) cell development with its canonical role being to antagonize E-protein function and alternate lineage fate. Here we have identified a key role for Id2 in regulating interleukin-15 (IL-15) receptor signaling and homeostasis of NK cells by repressing multiple E-protein target genes including Socs3. Id2 deletion in mature NK cells was incompatible with their homeostasis due to impaired IL-15 receptor signaling and metabolic function and this could be rescued by strong IL-15 receptor stimulation or genetic ablation of Socs3. During NK cell maturation, we observed an inverse correlation between E-protein target genes and Id2. These results shift the current paradigm on the role of ID2, indicating that it is required not only to antagonize E-proteins during NK cell commitment, but constantly required to titrate E-protein activity to regulate NK cell fitness and responsiveness to IL-15.

    DOI: 10.1016/j.immuni.2015.12.007

    Web of Science

    PubMed

    researchmap

  • レシピエントに対する移植前評価としてのHCT-CI/年齢スコアの臨床的意義(The clinical relevance of HCT-CI/age score as pre-transplant assessment for recipients)

    Katagiri Takayuki, Shibasaki Yasuhiko, Suwabe Tatsuya, Miyakoshi Shukuko, Fuse Kyoko, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   56 ( 9 )   1665 - 1665   2015.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Possible Involvement of Lung Cells Harboring an Abnormal Karyotype in the Pathogenesis of Pulmonary Alveolar Proteinosis Associated with Myelodysplastic Syndrome. Reviewed

    Moriyama M, Yano T, Furukawa T, Takada T, Ushiki T, Masuko M, Takizawa J, Sone H, Tazawa R, Saijo Y, Ishii H, Nakata K

    Annals of the American Thoracic Society   12 ( 8 )   1251 - 1253   2015.8

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1513/AnnalsATS.201503-175LE

    PubMed

    researchmap

  • The association of level of reduction of Wilms' tumor gene 1 mRNA transcript in bone marrow and outcome in acute myeloid leukemia patients Reviewed

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    LEUKEMIA RESEARCH   39 ( 6 )   667 - 671   2015.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PERGAMON-ELSEVIER SCIENCE LTD  

    We focused on the level of reduction of Wilms' tumor gene 1 (WT1) mRNA in bone marrow as minimal residual disease during chemotherapies in adult acute myeloid leukemia (AML) patients. Forty-eight patients were enrolled in this study. Log levels of reduction of WT1 mRNA transcript after induction therapy compared with those at diagnosis were associated with disease-free survival (DFS) (P = 0.0066) and overall survival (OS) (P = 0.0074) in patients who achieved complete remission. Also log levels of reduction of WT1 mRNA transcript after final consolidation therapy compared with those at diagnosis were associated with DFS (P = 0.015) and OS (P = 0.012). By multivariate analysis, log levels of reduction of WT1 mRNA transcript after induction therapy and after final consolidation therapy compared with those at diagnosis were extracted as risk factors for outcome. Our results suggest that early and deep reduction of tumor burden may be important for the outcome of AML patients. In addition, it may be useful for the decision to proceed with allogeneic SCT as post-remission therapy. (C) 2015 Elsevier Ltd. All rights reserved.

    DOI: 10.1016/j.leukres.2015.03.021

    Web of Science

    PubMed

    researchmap

  • Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy Reviewed

    Yasuhiko Shibasaki, Yoshinobu Seki, Tomoyuki Tanaka, Syukuko Miyakoshi, Kyoko Fuse, Takashi Kozakai, Hironori Kobayashi, Takashi Ushiki, Takashi Abe, Toshio Yano, Masato Moriyama, Takashi Kuroha, Noriatsu Isahai, Jun Takizawa, Miwako Narita, Satoru Koyama, Tatsuo Furukawa, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual-Energy CT Reviewed

    Hironori Kobayashi, Norihiko Yoshimura, Takashi Ushiki, Yasuhiko Shibasaki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   124 ( 21 )   2014.12

     More details

    Language:English   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • [Successful treatment of acute promyelocytic leukemia complicated with autoimmune hepatitis-induced portal hypertension with all-trans retinoic acid]. Reviewed

    Takashi Ushiki, Koji Nikkuni, Chie Yoshida, Yasuhiko Shibasaki, Toru Ishikawa, Masayoshi Masuko, Kazue Takai

    [Rinsho ketsueki] The Japanese journal of clinical hematology   53 ( 1 )   97 - 104   2012.1

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 35-year-old man admitted to the hospital for oral hemorrhage was diagnosed with acute promyelocytic leukemia (APL). Remission from APL was achieved by induction therapy with all-trans retinoic acid (ATRA); the PML/RARA fusion gene was not detected on PCR analysis. Despite complete molecular remission, severe persistent pancytopenia, massive ascites, and renal failure were observed. The liver surface appeared rough and irregular on computed tomographic images. On the basis of the liver biopsy results, we diagnosed his condition as portal hypertension due to autoimmune hepatitis. Indocyanine green test showed good residual function of the liver, and therefore, 2 courses of consolidation therapy were administered; chemotherapy was stopped because of severe pancytopenia due to portal hypertension. Instead of continuing the consolidation therapy, maintenance therapy involving 8 rounds of ATRA monotherapy (45 mg/m(2), days1∼14) was initiated. Portal hypertension did not progress further with this maintenance therapy and therefore it was continued. The patient has been in remission from APL ever since, and no relapses have occurred since the past 5 years. These results suggest that ATRA can be used for long-term therapy in such cases.

    PubMed

    researchmap

  • [Cardiogenic shock due to takotsubo cardiomyopathy during induction therapy for acute myeloid leukemia]. Reviewed

    Takashi Ushiki, Koji Nikkuni, Yuya Ishikawa, Yasuhiko Shibasaki, Yukio Hosaka, Masayoshi Masuko, Kazue Takai

    [Rinsho ketsueki] The Japanese journal of clinical hematology   52 ( 12 )   1896 - 9   2011.12

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 61-year-old man admitted for pancytopenia was diagnosed with acute myeloid leukemia. On day 26 of induction therapy, the patient suddenly developed cardiogenic shock. The ultrasound cardiogram showed imaging features typical of takotsubo cardiomyopathy. Cardiogenic shock caused by takotsubo cardiomyopathy is rare in patients with hematological malignancies but is a severe complication during chemotherapy.

    PubMed

    researchmap

  • [Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow]. Reviewed

    Kazue Takai, Takashi Ushiki, Koji Nikkuni, Hideki Hashidate, Hiroyuki Shibuya

    [Rinsho ketsueki] The Japanese journal of clinical hematology   52 ( 2 )   73 - 7   2011.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 52-year-old woman presented with isolated thrombocytosis in 2003. After 5 years of observation under a tentative diagnosis of essential thrombocythemia (ET), she was referred to our hospital because of anemia and leukopenia. Bone marrow biopsy demonstrated increases of megakaryocytes and myelofibrosis, but splenomegaly was absent. A karyotype study of bone marrow detected t(9;22) (q34;q11.2) in 6 of the 20 metaphases studied. Peripheral blood neutrophil BCA-ABL fusion signals (FISH) were not detected. Because RT-PCR assay of bone marrow detected major-BCR-ABL mRNA (b3a2), treatment with imatinib (400 mg/day) was started. After transient thrombocytopenia, normalization of blood cell counts and improvement of myelofibrosis were achieved. JAK2 V617F mutation and M-BCR-ABL mRNA was negative in peripheral blood. Clinical and laboratory data suggest that this case represents a rare and atypical myeloproliferative neoplasm with BCR-ABL translocation restricted mainly to the megakaryocyte lineage.

    PubMed

    researchmap

  • Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia Reviewed

    Kaori Karimata, Masayoshi Masuko, Takashi Ushiki, Takashi Kozakai, Yasuhiko Shibasaki, Toshio Yano, Takashi Abe, Masato Moriyama, Ken Toba, Tatsuo Furukawa, Yoshifusa Aizawa

    INTERNAL MEDICINE   50 ( 5 )   481 - 485   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We describe a 60-year-old Japanese patient with chronic myeloid leukemia (CML) who developed myelodysplastic syndrome (MDS) with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment. Most cases that developed chromosomal abnormality in Ph negative cells during imatinib therapy were reported to have less clinical implications, while rare cases developed MDS/AML. The present case suggested that metaphase karyotype analysis and bone marrow examination should be performed for the long term follow-up under imatinib treatment in cases showing cytopenia. The results also suggested that monosomy 7 in Ph negative cells may be an indicator of a poor prognosis.

    DOI: 10.2169/internalmedicine.50.4481

    Web of Science

    PubMed

    researchmap

  • Multimodality Imaging of Subcutaneous Panniculitis-like T-cell Lymphoma Reviewed

    Takashi Ushiki, Koji Nikkuni, Takeshi Higuchi, Kazue Takai

    INTERNAL MEDICINE   50 ( 11 )   1265 - 1265   2011

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publisher:JAPAN SOC INTERNAL MEDICINE  

    DOI: 10.2169/internalmedicine.50.5338

    Web of Science

    PubMed

    researchmap

  • Successful Remission of Evans Syndrome Associated with Graves&apos; Disease by Using Propylthiouracil Monotherapy Reviewed

    Takashi Ushiki, Masayoshi Masuko, Koji Nikkuni, Jun Terukina-Yoshida, Ayako Momotsu-Nanba, Hiroshi Morikawa, Akio Usami, Ichiro Fuse, Ken Toba, Kazue Takai, Yoshifusa Aizawa

    INTERNAL MEDICINE   50 ( 6 )   621 - 625   2011

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    A 46-year-old woman with Graves&apos; disease was admitted for anemia and thrombocytopenia. She had previously been treated with methimazole but she self-discontinued the treatment 6 months prior to admission. She was diagnosed with Evans syndrome associated with Graves&apos; disease and treated with propylthiouracil without corticosteroids, which normalized her thyroglobulin level. Surprisingly, while Evans syndrome is characterized by frequent relapses, this patient has been in remission of Evans syndrome for approximately 4 years. The remission of Evans syndrome associated with Graves&apos; disease in the absence of immunosuppressive therapy suggests that these 2 diseases have a common pathogenetic mechanism.

    DOI: 10.2169/internalmedicine.50.4319

    Web of Science

    PubMed

    researchmap

  • Early Protective Effect of Bone Marrow Mononuclear Cells Against Ischemic White Matter Damage Through Augmentation of Cerebral Blood Flow Reviewed

    Youshi Fujita, Masafumi Ihara, Takashi Ushiki, Hideyo Hirai, Shinae Kizaka-Kondoh, Masahiro Hiraoka, Hidefumi Ito, Ryosuke Takahashi

    STROKE   41 ( 12 )   2938 - 2943   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Background and Purpose-To investigate the efficacy of bone marrow mononuclear cell (BMMNC) treatment against ischemic white matter (WM) damage in a hypoperfused brain.
    Methods-Mice were administered intravenous treatment of vehicle, spleen-derived marrow mononuclear cells (MNCs), or BMMNCs (5X10(6) cells) obtained from enhanced green fluorescent protein transgenic mice 24 hours after bilateral common carotid artery stenosis (BCAS), and then euthanized at either 1 day or 30 days after treatment.
    Results-Laser speckle perfusion imaging analyses revealed marked recovery of cerebral blood flow (CBF) in the early phase after BMMNC treatment (6 hours after administration), before histological evidence of angiogenesis was assessed by fluorescein-isothiocyanate-dextran perfusion assay. BMMNC treatment induced an increase in vascular endothelial growth factor and Ser1177 phosphorylated endothelial nitric oxide synthase levels in the BCAS-induced mouse brains at 1 day after the treatment. BCAS-induced ischemic WM lesions were significantly improved 30 days after BMMNC treatment despite any evidence of direct structural incorporation of donor BMMNCs into endothelial cells and oligodendrocytes. Instead, enhanced green fluorescent protein-positive donor cells with morphological features of pericytes were observed in the vessel walls. Post-BMMNC administration of an NOS inhibitor abolished early CBF recovery and produced protective effects against ischemic WM damage.
    Conclusions-BMMNC treatment provides marked protection against ischemic WM damage, enhancing CBF in the early phase and in subsequent angiogenesis, both of which involve nitric oxide synthase activation. These findings suggest promise for the application of BMMNCs for subcortical ischemic vascular dementia. (Stroke. 2010;41:2938-2943.)

    DOI: 10.1161/STROKEAHA.110.596379

    Web of Science

    PubMed

    researchmap

  • In Vivo Imaging of HIF-Active Tumors by an Oxygen-Dependent Degradation Protein Probe with an Interchangeable Labeling System Reviewed

    Takahiro Kuchimaru, Tetsuya Kadonosono, Shotaro Tanaka, Takashi Ushiki, Masahiro Hiraoka, Shinae Kizaka-Kondoh

    PLOS ONE   5 ( 12 )   e15736   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PUBLIC LIBRARY SCIENCE  

    Hypoxia-inducible factor (HIF) functions as a master transcriptional regulator for adaptation to hypoxia by inducing adaptive changes in gene expression for regulation of proliferation, angiogenesis, apoptosis and energy metabolism. Cancers with high expression of the alpha subunit of HIF (HIF alpha) are often malignant and treatment-resistant. Therefore, the development of a molecular probe that can detect HIF activity has great potential value for monitoring tumor hypoxia. HIF prolyl hydroxylases (HPHDs) act as oxygen sensors that regulate the fate of HIF alpha protein through its oxygen-dependent degradation (ODD) domain. We constructed a recombinant protein PTD-ODD-HaloTag (POH) that is under the same ODD regulation as HIF alpha and contains protein transduction domain (PTD) and an interchangeable labeling system. Administration of near-infrared fluorescently labeled POH (POH-N) to mouse models of cancers allowed successful monitoring of HIF-active regions. Immunohistochemical analysis for intratumoral localization of POH probe revealed its specificity to HIF-active cells. Furthermore, lack of the PTD domain or a point mutation in the ODD domain abrogated the specificity of POH-N to HIF-active cells. Overall results indicate that POH is a practical probe specific to HIF-active cell in cancers and suggest its large potential for imaging and targeting of HIF-related diseases.

    DOI: 10.1371/journal.pone.0015736

    Web of Science

    PubMed

    researchmap

  • Noninvasive Tracking of Donor Cell Homing by Near-Infrared Fluorescence Imaging Shortly after Bone Marrow Transplantation Reviewed

    Takashi Ushiki, Shinae Kizaka-Kondoh, Eishi Ashihara, Shotaro Tanaka, Masayoshi Masuko, Hideyo Hirai, Shinya Kimura, Yoshifusa Aizawa, Taira Maekawa, Masahiro Hiraoka

    PLOS ONE   5 ( 6 )   e11114   2010.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:PUBLIC LIBRARY SCIENCE  

    Background: Many diseases associated with bone marrow transplantation (BMT) are caused by transplanted hematopoietic cells, and the onset of these diseases occurs after homing of donor cells in the initial phase after BMT. Noninvasive observation of donor cell homing shortly after transplantation is potentially valuable for improving therapeutic outcomes of BMT by diagnosing the early stages of these diseases.
    Methodology/Principal Findings: Freshly harvested near-infrared fluorescence-labeled cells were noninvasively observed for 24 h after BMT using a photon counting device to track their homing process. In a congenic BMT model, the homing of Alexa Fluor 750-labeled donor cells in the tibia was detected less than 1 h after BMT. In addition, subsequent cell distribution in an intraBM BMT model was successfully monitored for the first time using this method. In the allogeneic BMT model, T-cell depletion decreased the near-infrared fluorescence (NIRF) signals of the reticuloendothelial system.
    Conclusions/Significance: This approach in several murine BMT models revealed that the transplanted cells homed within 24 h after transplantation. NIRF labeling is useful for tracking transplanted cells in the initial phase after BMT, and this approach can contribute to in vivo studies aimed at improving the therapeutic outcomes of BMT.

    DOI: 10.1371/journal.pone.0011114

    Web of Science

    PubMed

    researchmap

  • Therapeutic Efficacy of Continuous Arterial Infusion of the Protease Inhibitor and the Antibiotics and via Celiac and Superior Mesenteric Artery for Severe Acute Pancreatitis-Pilot Study Reviewed

    Toru Ishikawa, Michitaka Imai, Hiroteru Kamimura, Takashi Ushiki, Atsunori Tsuchiya, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Tomoteru Kamimura

    HEPATO-GASTROENTEROLOGY   56 ( 90 )   524 - 528   2009.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:H G E UPDATE MEDICAL PUBLISHING S A  

    Background/Aims: Severe acute pancreatitis is poor prognosis. Continuous regional arterial infusion of protease inhibitors and antibiotics were developed in Japan. We evaluated whether arterial infusion both celiac artery and superior mesenteric artery for this disease would reduce mortality.
    Methodology: Seventeen patients were treated arterial infusion of protease inhibitor and antibiotics via both celiac artery and superior mesenteric artery. Changes of Acute Physiology and Chronic Health Evaluation II score and mortality were evaluated.
    Results: Arterial infusion via two routes reduced the mortality rate and improved Acute Physiology and Chronic Health Evaluation II score. The overall mortality rate was 11.8%. The mortality rate in patients in whom were treated within Mays after the onset was significantly lower than that in patients in whom were treated without 3days after the onset
    Conclusions: Arterial infusion via superior mesenteric artery might prevent both bacterial translocation and non-occlusive mesenteric ischemia. Continuous arterial infusion both celiac artery and superior mesenteric artery might be effective for reducing mortality and preventing the development of pancreatitis, especially when initiated within Mays after the onset. Further prospective randomized studies using a larger number of patients are required.

    Web of Science

    PubMed

    researchmap

  • Intravenously administered bone marrow cells alleviates white matter lesions in a model of chronic cerebral hypoperfusion Reviewed

    Youshi Fujita, Takashi Ushiki, Masafumi Ihara, Hidefumi Ito, Shinae Kizaka-Kondoh, Ryosuke Takahashi

    NEUROSCIENCE RESEARCH   65   S123 - S123   2009

     More details

    Language:English   Publisher:ELSEVIER IRELAND LTD  

    Youshi Fujita, Takashi Ushiki, Masafumi Ihara, Hidefumi Ito, Shinae Kizaka-Kondoh, Ryosuke Takahashi, 2009, &#039;Intravenously administered bone marrow cells alleviates white matter lesions in a model of chronic cerebral hypoperfusion&#039;, &lt;i&gt;Neuroscience Research&lt;/i&gt;, vol. 65, p. S123

    DOI: 10.1016/j.neures.2009.09.586

    Web of Science

    researchmap

  • 高齢者切除不能膵癌に対する動注化学療法

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    老年消化器病   18 ( 1 )   55 - 59   2007.6

     More details

    Language:Japanese   Publisher:(株)アークメディア  

    高齢者切除不能膵癌患者に動注化学療法を施行し、局所療法として本治療法が症状緩和を含めた緩和治療の一方法となりうるか検討した。切除不能膵癌患者で、動注化学療法を施行した18例を65歳以上の高齢者群10例と65歳未満の非高齢者群8例の2群に分け、生存期間、症状緩和効果、在宅期間率、副作用を比較検討した。高齢者群に女性の比率が高い傾向を認めた。全体の50%生存期間は293日で、6ヵ月生存率は76.2%、1年生存率は30.4%であった。Kaplan-Meier法による生存曲線では、50%生存期間は非高齢者群242日、高齢者群は301日で有意差は認めなかった。全体の症状緩和効果は77.7%、Tumor Responseは50.0%、CA19-9 Responseは55.5%であった。高齢者群10例中8例、非高齢者群8例中6例に症状緩和効果を認め、全例外来治療に移行できた。

    researchmap

  • Angiotensin-II administration is useful for the detection of liver metastasis from pancreatic cancer during pharmacoangiographic computed tomography Reviewed

    Toru Ishikawa, Takashi Ushiki, Hiroteru Kamimura, Tadayuki Togashi, Atsunori Tsuchiya, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Keiko Takeda, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   13 ( 22 )   3080 - 3083   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:W J G PRESS  

    AIM: To improve the preoperative diagnosis of liver metastasis from pancreatic cancer, we estimated computed tomography during arterial angiography (CTA) with/without administration of angiotensin-II (AT-II).
    METHODS: Thirty-five patients with pancreatic cancer were examined in this study. After conventional CTA was performed, pharmacoangiographic CTA was performed with a 1-3 microgram/5 mL solution of angiotensin II injected through a catheter into the celiac artery during spiral computed tomography. We prospectively analyzed the relative region of interest (ROI) ratio of tumor to liver with/without AT-II.
    RESULTS: In all patients, the relative ratio of each computed tomography (CT) number in the ROI was larger at pharmacoangiographic CT than at conventional angiographic CT. Administration of angiotensin-II enhanced the metastatic liver tumor as compared with normal tissue. Intratumoral blood flow increased in all patients with malignant tumors due to the pressure effect of AT-II. Furthermore, the metastatic lesions in the liver of three patients were represented by only pharmacoangiographic CT, not by conventional CT and conventional CT angiography. In even peripheral and central areas of metastatic liver tumor, the lesions were enhanced after administration of AT-II.
    CONCLUSION: These results support that high detection rate of liver metastasis revealed by pharmacoangiographic CT suggests the improvement of diagnosis on preoperative staging. Moreover, chemotherapy under AT-II induced hypertension may have a better effect on the treatment of metastatic liver tumors. (c) 2007 The WJG Press. All rights reserved.

    Web of Science

    PubMed

    researchmap

  • [A case of splenic inflammatory pseudotumor]. Reviewed

    Toru Ishikawa, Takashi Ushiki, Tadayuki Togashi, Kouji Watanabe, Keiichi Seki, Hironobu Oota, Toshiaki Yoshida, Tomoteru Kamimura, Nobuyuki Musha, Toshihiro Tsubono, Yasuo Sakai, Keiko Takeda, Noriko Ishihara

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology   104 ( 3 )   407 - 12   2007.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 59-year-old man was admitted to our hospital because of continuous C-reactive protein elevation. Abdominal computed tomography scan revealed a low density mass on the surface of the spleen. Magnetic resonance imaging showed low intensity at peripheral area and slightly high intensity in the central area of the mass lesion on T1 and T2-weighted image. Splenectomy was performed since we could not rule out the possibility of malignant neoplasm only by diagnostic imaging. The pathological diagnosis of the tumor was inflammatory pseudotumor. Splenectomy is considered to be significant from the standpoints of both diagnosis and therapy in cases in which diagnostic imaging is difficult to interpret.

    PubMed

    researchmap

  • 重症急性膵炎に伴う急性肺障害に対する好中球エラスターゼ阻害薬(sivelestat sodium)の有用性

    石川 達, 牛木 隆志, 今井 径卓, 上村 博輝, 土屋 淳紀, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    Progress in Medicine   27 ( 2 )   409 - 412   2007.2

     More details

    Language:Japanese   Publisher:(株)ライフ・サイエンス  

    症例1:56歳男。心窩部痛が増悪し、ショック状態を来たした。検査所見で白血球数、amylaseなどの上昇、CTで両側傍腎腔の液体貯留などを認め、急性膵炎、Grade Vと診断し、APACHE II scoreも11点であったため、蛋白分解酵素阻害薬および抗菌薬の動注療法を行った。加療開始後改善傾向を認めたが、全身性炎症反応症候群に伴う急性肺障害を合併したため、人工呼吸管理と同時にsivelestat sodium、利尿薬、アルブミン製剤の投与を開始した。病態は改善し6日間で抜管でき、内科的治療の継続により退院となった。症例2:27歳男。腹痛が増悪し、ショック状態となった。CTで膵融解像、膵・腎周囲滲出液を認め、急性膵炎、Grade IV、APACHE II score 8点と診断し、動注療法および持続血液濾過透析を施行した。更に、PaO2/FIO2比の低下傾向を認めたため、急性呼吸窮迫症候群の危険性を考えsivelestat sodiumを併用した。その結果、早期改善を認め、発症23日で退院した。

    researchmap

  • [Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer]. Reviewed

    Hironobu Ohta, Takashi Ushiki, Ken-ichi Mizuno, Tadayuki Togashi, Kouji Watanabe, Keiichi Seki, Tooru Ishikawa, Toshiaki Yoshida, Tomoteru Kamimura, Yasuyuki Baba, Yoshirou Mafune, Naoki Ishikawa

    Gan to kagaku ryoho. Cancer & chemotherapy   33 ( 9 )   1267 - 71   2006.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Gemcitabine hydrochloride (GEM) is a first-line therapeutic agent for advanced pancreatic cancer, but there is no established second-line treatment after GEM failure. We assessed the clinical benefit of systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in 19 patients compared with GEM in 32 patients, respectively. Tumor response rates were 10.5% and 15.6% for FP therapy and GEM, respectively. The median survival time in the FP therapy and GEM was 137 days and 241 days, respectively. Although clinical benefit was similar in both types of therapy, median survival time was more favorable for GEM, especially for Stage IVb. Nausea and vomiting were the most commonly observed toxicity in the FP therapy group. Our data indicate that FP therapy is not considered to be a useful second-line agent in patients with GEM pretreated pancreatic cancer.

    PubMed

    researchmap

  • CT-maximum intensity projection is a clinically useful modality for the detection of gastric varices Reviewed

    Toru Ishikawa, Takashi Ushiki, Ken-ichi Mizuno, Tadayuki Togashi, Kouji Watanabe, Kei-ichi Seki, Hironobu Ohta, Toshiaki Yoshida, Keiko Takeda, Tomoteru Kamimura

    WORLD JOURNAL OF GASTROENTEROLOGY   11 ( 47 )   7515 - 7519   2005.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BAISHIDENG PUBL GRP CO LTD  

    AIM: To evaluate the efficacy of CT-maximum intensity projection (CT-MIP) in the detection of gastric varices and their inflowing and outflowing vessels in patients with gastric varices scheduled to undergo balloon-occluded retrograde transvenous obliteration (B-RTO).
    METHODS: Sixteen patients with endoscopically confirmed gastric varices were included in this study. All patients were evaluated with CT-MIP using three-dimensional reconstructions, before and after B-RTO.
    RESULTS: CT-MIP clearly depicted gastric varices in 16 patients (100%), the left gastric vein in 6 (32.5%), the posterior gastric vein in 12 (75.0%), the short gastric veins in 13 (81.3%), gastrorenal shunts in 16 (100%), the hemiazygos vein (HAZV) in 4 (25.0%), the pericardiophrenic vein (PCPV) in 9 (56.3%), and the left inferior phrenic vein in 9 patients (56.3%). Although flow direction itself cannot be determined from CT-MIP, this modality provided clear images of the inflowing and the outflowing vessels. Moreover, in one patient, short gastric veins were not seen on conventional angiographic portography images of the spleen, but were clearly revealed on CT-MIP.
    CONCLUSION: We suggest that CT-MIP should be considered as a routine method for detecting and diagnosing collateral veins in patients with gastric varices scheduled for B-RTO. Furthermore, CT-MIP is more useful than endoscopy in verifying the early therapeutic effects of B-RTO. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.

    Web of Science

    PubMed

    researchmap

  • Balloon-occluded retrograde transvenous obliteration of gastric varix draining to the IVC via the circurnaortic renal vein Reviewed

    T Ishikawa, T Ushiki, K Mizuno, T Togashi, K Watanabe, Y Baba, K Seki, H Ohta, T Yoshida, K Takeda, T Kamimura

    HEPATOLOGY RESEARCH   32 ( 2 )   117 - 120   2005.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER IRELAND LTD  

    The authors encountered a patient with gastric varices draining to the IVC not only via the usual route of the left renal vein but also via a circumaortic renal vein. Balloon-occluded retrograde transvenous obliteration (B-RTO) of the gastric varix was performed with balloon occlusion of the circumaortic renal vein and retrograde injection of sclerosing agent (5% of ethanolamine oleate) into the varix. Eradication of the gastric varix was confirmed on endoscopic examination 2 months later. We document the first case of B-RTO performed for gastric varix via the circumaortic renal vein. Details of this rare occurrence and implications for treatment are presented herein. (c) 2005 Elsevier B.V. All rights reserved.

    DOI: 10.1016/j.hepres.2005.03.011

    Web of Science

    PubMed

    researchmap

▶ display all

Books

  • AU2022: REFLECTIONS A Novel Method of CD31 Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody Mediated Rejection in ABO-Incompatible Kidney Transplantation

    Masayuki Tasaki, Hiroaki Tateno, Takashi Sato, Azusa Tomioka, Hiroyuki Kaji, Hisashi Narimatsu, Kazuhide Saito, Yuki Nakagawa, Toshinari Aoki, Masami Kamimura, Takashi Ushiki, Manabu Okada, Yuko Miwa, Kiyohiko Hotta, Yutaka Yoshida, Kota Takahashi, Yoshihiko Tomita( Role: Joint author)

    AUA news (the official newsmagazine of the American Urological Association)  2022.10 

     More details

MISC

  • Adverse events during preoperative autologous blood donation and its usage in obstetrical patients: A multicenter, retrospective study in Japan

    A Yokohama, H Fujita, K Nagai, SI Fujiwara, K Tanimoto, T Ushiki, T Henzan, Y Hatta, R Yanagisawa, K Watanabe, J Murakami, Y Hasegawa, K Ikeda, K Fujino, M Matsumoto, A Tanaka, S Makino, S Kino, A Takeshita, K Muroi

    38th International Congress of the ISBT (International Society of Blood Transfusion)   2024.6

     More details

  • 高脂肪食により誘発される造血細胞移植後GVHDへの炎症抑制因子SOCSの関与

    石黒 創, Sijia Wu, 小林孝也, 土田拓睦, 諏訪部達也, 荒木雅弥, 横田明日美, 中川嘉, 平位秀世, 進藤岳郎, 曽根博仁, 増子正義, 牛木隆志

    第67回 日本糖尿病学会学術総会   2024.5

     More details

  • 輸血後肝障害アラートメールシステム導入による輸血後感染症検査中止に対する補完機能の検証

    佐藤美里, 上村正巳, 鈴木克弥, 大木直江, 川合綾野, 山藤菜々子, 須貝景斗, 阿部理一郎, 布施香子, 牛木隆志

    第72回日本輸血・細胞治療学会学術集会   2024.5

     More details

  • 女性アスリートにおける白血球入り多血小板血漿は健常女性に比して抗炎症性サイトカインを豊富に含んでいる

    望月友晴, 牛木隆志, 江玉 睦明, 大森 豪, 川瀬知之

    第23回日本再生医療学会総会   2024.3

     More details

  • アスリートにおける多血小板血漿組成の性差に関する横断的比較研究

    川瀬知之, 望月友晴, 江玉 睦明, 渡邉 聡, 大森 豪, 牛木隆志

    第23回日本再生医療学会総会   2024.3

     More details

  • プロアスリートに対する多血小板血漿治療のエビデンス: (Ⅱ) 血小板ATPに関する基礎的研究

    牛木隆志, 望月友晴, 鈴木克弥, 渡辺真理, 藤本 陽子, 布施 香子, 江玉 睦明, 渡邉 聡, 大森 豪, 川瀬知之

    第23回日本再生医療学会総会   2024.3

     More details

  • 同種造血幹細胞移植後にCOVID-19再活性化が致命的となった再生不良性貧血の一例

    諏訪部達也, 古山悠里, 米沢穂高, 片桐隆幸, 布施香子, 柴崎康彦, 牛木隆志, 曽根博仁, 増子正義

    第46回日本造血・免疫細胞療法学会総会   2024.3

     More details

  • 当院における新生児輸血と製剤分割の現状について

    須貝景斗, 鈴木克弥, 上村正巳, 佐藤美里, 山藤菜々子, 大木直江, 川合綾野, 牛木隆志, 布施香子

    第157回 日本輸血・細胞治療学会関東甲信越支部例会   2024.2

     More details

  • Decade-long WT1-specific cytotoxic T lymphocyte induced by WT1 peptide vaccine

    Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Tori Ida, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

    第85回日本血液学会学術集会   2023.10

     More details

  • アルブミン血漿交換療法によるFFP使用量削減効果の検証

    鈴木克弥, 上村正巳, 佐藤美里, 山藤菜々子, 大木直江, 川合綾野, 長谷川進, 上杉雅子, 山本 卓, 布施香子, 牛木隆志

    第71回日本輸血・細胞治療学会学術総会   2023.5

     More details

  • ABO不適合腎移植における抗体関連型拒絶反応を予測する新規抗体価測定法(CD31-ABOマイクロアレイ)の開発(A novel method of CD31 combined ABO carbohydrate antigen microarray predicts acute antibody mediated rejection in ABO-incompatible kidney transplantation)

    田崎 正行, 舘野 浩章, 佐藤 隆, 富岡 あづさ, 梶 裕之, 青木 寿成, 上村 正巳, 牛木 隆志, 齋藤 和英, 成松 久, 高橋 公太, 冨田 善彦

    日本泌尿器科学会総会   110回   AOP14 - 01   2023.4

     More details

    Language:English   Publisher:(一社)日本泌尿器科学会総会事務局  

    researchmap

  • プロアスリートに対する多血小板血漿治療のエビデンス: (I) 血小板ポリリン酸に関する基礎的研究

    望月友晴, 牛木隆志, 谷藤 理, 川島寛之, 川瀬知之

    第22回日本再生医療学会総会   2023.3

     More details

  • 新潟大学において血液学研究を発展させる

    牛木 隆志

    第12回知の広場サイエンスセミナー(新潟大学医学部医学科)   2023.3

     More details

  • 当院におけるT&S推進と廃棄血削減の取り組みについて

    山藤菜々子, 佐藤美里, 上村正巳, 鈴木克弥, 大木直江, 川合綾野, 阿部理一郎, 牛木隆志, 布施香子

    第155回 日本輸血・細胞治療学会関東甲信越支部例会   2023.2

     More details

  • キノロン系抗生剤の予防投与を行わない同種造血幹細胞移植における血流感染症

    諏訪部達也, 布施香子, 片桐隆幸, 牛木隆志, 柴崎康彦, 曽根博仁, 増子正義

    第45回日本造血・免疫細胞療法学会総会   2023.2

     More details

  • WT1ペプチドワクチン投与後10年間以上にわたり持続するWT1特異的な細胞傷害性T細胞

    諏訪部 達也, 柴崎 康彦, 田村 秀, 片桐 隆幸, 井田 桃里, 布施 香子, 牛木 隆志, 曽根 博仁, 成田 美和子, 増子 正義

    日本血液学会学術集会   84回   117 - 117   2022.10

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • 腎血管内皮細胞特異的抗血液型抗体測定法の開発

    田崎 正行, 舘野 浩章, 佐藤 隆, 梶 裕之, 富岡 あづさ, 齋藤 和英, 青木 寿成, 上村 正巳, 牛木 隆志, 吉田 豊, 高橋 公太, 冨田 善彦

    移植   57 ( 総会臨時 )   324 - 324   2022.10

  • 腎血管内皮細胞特異的抗血液型抗体測定法の開発

    田崎 正行, 舘野 浩章, 佐藤 隆, 梶 裕之, 富岡 あづさ, 齋藤 和英, 青木 寿成, 上村 正巳, 牛木 隆志, 吉田 豊, 高橋 公太, 冨田 善彦

    第58回日本移植学会総会   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本移植学会  

    researchmap

  • Easy clot characteristics of the placenta in a case of congenital hypofibrinogenemia.

    Y. Seki, T. Ushiki, M. Masuko, J. Takizawa, H. Sone, N. Okumura

    International Society on Thrombosis and Haemostasis 2022 Congress   2022.7

     More details

  • 先天性低フィブリノゲン血症症例の易血栓性胎盤

    関 義信, 牛木隆志, 増子正義, 瀧澤 淳, 曽根博仁, 奥村伸生

    第44回日本血栓止血学会学術集会   2022.6

     More details

  • A Novel Method of CD31-Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation

    Masayuki Tasaki, Hiroaki Tateno, Takashi Sato, Azusa Tomioka, Hiroyuki Kaji, Hisashi Narimatsu, Kazuhide Saito, Yuki Nakagawa, Toshinari Aoki, Masami Kamimura, Takashi Ushiki, Manabu Okada, Yuko Miwa, Kiyohiko Hotta, Yutaka Yoshida, Kota Takahashi, Yoshihiko Tomita

    Transplant International   35   2022.5

     More details

    Publisher:Frontiers Media SA  

    Isohemagglutinin assays employing red blood cells (RBCs) are the most common assays used to measure antibody titer in ABO-incompatible kidney transplantation (ABOi KTx). However, ABO antigens expressed on RBCs are not identical to those of kidney and antibody titers do not always correlate with clinical outcome. We previously reported that CD31 was the main protein linked to ABO antigens on kidney endothelial cells (KECs), which was different from those on RBCs. We developed a new method to measure antibody titer using a microarray of recombinant CD31 (rCD31) linked to ABO antigens (CD31-ABO microarray). Mass spectrometry analysis suggested that rCD31 and native CD31 purified from human kidney had similar ABO glycan. To confirm clinical use of CD31-ABO microarray, a total of 252 plasma samples including volunteers, hemodialysis patients, and transplant recipients were examined. In transplant recipients, any initial IgG or IgM antibody intensity &amp;gt;30,000 against the donor blood type in the CD31-ABO microarray showed higher sensitivity, specificity, positive predictive value, and negative predictive value of AABMR, compared to isohemagglutinin assays. Use of a CD31-ABO microarray to determine antibody titer specifically against ABO antigens expressed on KECs will contribute to precisely predicting AABMR or preventing over immunosuppression following ABOi KTx.

    DOI: 10.3389/ti.2022.10248

    researchmap

  • 救急医療現場での緊急輸血における院内配送時間の検討

    上村正巳, 佐藤美里, 鈴木克弥, 松原千秋, 大木直江, 川合綾野, 小野寺 理, 新田正和, 牛木隆志

    第70回日本輸血・細胞治療学会学術集会   2022.5

     More details

  • The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms’ Tumor 1 Peptide Vaccination

    Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

    63rd ASH Annual Meeting and Exposition   2021.12

     More details

  • アルブミン血漿交換療法によるFFP 使用量削減効果の検証

    鈴木克弥,上村正巳,佐藤美里,大木直江,川合綾野,松原千秋,長谷川進,上杉雅子,山本卓,小野寺理,牛木隆志

    第152回 日本輸血・細胞治療学会 関東甲信越支部例会   2021.9

     More details

  • ドナーリンパ球のコンドロイチン硫酸合成低下はGVHDを軽減する(Genetic manipulation resulting in decreased donor chondroitin sulfate mitigates GVHD in mice)

    田村 秀, 牛木 隆志, 諏訪部 達也, 片桐 隆幸, 石黒 創, 布施 香子, 柴崎 康彦, 進藤 岳郎, 五十嵐 道弘, 曽根 博仁, 増子 正義

    日本血液学会学術集会   83回   OS3 - 1   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • WT1ペプチドワクチン投与後のCML患者におけるWT1特異的CTLの持続性と多様性(Persistence and diversity of WT1-specific CTLs in a CML patient vaccinated WT1 peptide)

    諏訪部 達也, 柴崎 康彦, 田村 秀, 片桐 隆幸, 布施 香子, 牛木 隆志, 曽根 博仁, 成田 美和子, 増子 正義

    日本血液学会学術集会   83回   PS - 1   2021.9

     More details

    Language:English   Publisher:(一社)日本血液学会  

    researchmap

  • A Patient with Congenital Hypofibrinogenemia who Showed Embryo Implantation, Continuation of Pregnancy, and Delivery Following Continuous Transfusion of Dry Human Fibrinogen Preparations

    Y. Seki, T. Ushiki, M. Masuko, J. Takizawa, H. Sone, N. Okumura

    International Society on Thrombosis and Haemostasis 2021 Congress   2021.7

     More details

  • 同種造血幹細胞移植後の慢性GVHDとしての類上皮肉芽腫および多発筋炎

    諏訪部 達也, 布施 香子, 水戸部 正樹, 武田 ルイ, 米沢 穂高, 片桐 隆幸, 河本 啓介, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 大島 孝一, 増子 正義

    臨床血液   62 ( 6 )   675 - 675   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Genetically Reduced Chondroitin Sulfate Prevents the Progression of Diabetic Neuropathy via Pericyte Functions

    Hajime Ishiguro, Takashi Ushiki, Atsuko Honda, Tadahisa Mikami, Hiroshi Kitagawa, Kazunori Sango, Masayoshi Masuko, Michihiro Igarashi, Hirohito Sone

    DIABETES   70   2021.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER DIABETES ASSOC  

    DOI: 10.2337/db21-421-P

    Web of Science

    researchmap

  • 乾燥人フィブリノゲン製剤の継続輸注で着床・妊娠継続・出産をし得た先天性低フィブリノゲン血症

    関 義信, 牛木 隆志, 増子 正義, 瀧澤 淳, 曽根 博仁, 奥村 伸生

    日本血栓止血学会誌   32 ( 2 )   214 - 214   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • Genetic Manipulation Resulting in Decreased Donor ChondroitinsulfateSynthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model

    Suguru Tamura, Takashi Ushiki, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Michihiro Igarashi, Hirohito Sone, Masayoshi Masuko

    BLOOD   136   2020.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2020-137448

    Web of Science

    researchmap

  • 骨髄異形成症候群におけるWT1特異的CD8+T細胞の存在分布と表現型に関する検討

    諏訪部達也, 佐藤廣幸, 田村秀, 片桐隆幸, 笠見卓哉, 根本洋樹, 小堺貴司, 難波亜矢子, 北嶋俊樹, 布施香子, 牛木隆志, 曽根博仁, 成田美和子, 増子正義

    第12回日本血液疾患免疫療法学会学術集会   2020.9

     More details

  • 新潟県における県内共通版不規則抗体カードの現状

    鈴木 克弥, 見邉 典子, 木島 貴志, 高橋 一哲, 古俣 妙, 佐藤 美里, 上村 正巳, 牛木 隆志, 関 義信, 新潟県合同輸血療法委員会

    日本輸血細胞治療学会誌   66 ( 2 )   302 - 302   2020.5

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Micro Typing Systemによる不規則抗体検査実施施設における生後4ヵ月未満児での非溶血性輸血副作用発生状況

    上村 正巳, 佐藤 美里, 青木 寿成, 大木 直江, 川合 綾野, 松原 千秋, 藤本 陽子, 渡辺 真里, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   66 ( 2 )   411 - 411   2020.5

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 機能的なWT1特異的CD8陽性T細胞クローンは骨髄異形成症候群の骨髄内に集積する

    諏訪部達也, 柴崎康彦, 佐藤廣幸, 田村秀, 片桐隆幸, 根本洋樹, 笠見卓哉, 小堺貴司, 難波亜矢子, 北嶋俊樹, 布施香子, 牛木隆志, 曽根博仁, 成田美和子, 増子正義

    日本血液学会学術集会抄録(Web)   82nd   2020

  • 造血細胞と骨髄間質のコンドロイチン硫酸は異なる造血調節作用を示す

    片桐隆幸, 牛木隆志, 中島やえ子, 大島基彦, 三上雅久, 河嵜麻実, 石黒創, 田中智之, 曽根博仁, 北川裕之, 五十嵐道弘, 岩間厚志, 増子正義

    日本血液学会学術集会抄録(Web)   82nd   2020

  • 骨髄異形成症候群と低悪性度B細胞リンパ腫を合併し、多彩な合併症を呈した1例

    海發 茜, 小堺 貴司, 田村 秀, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 布施 香子, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   60 ( 10 )   1503 - 1503   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Micro Typing Systemによる生後4ヵ月未満児不規則抗体検査

    上村 正巳, 青木 寿成, 佐藤 美里, 渡部 もも, 大木 直江, 川合 綾野, 増子 正義, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   65 ( 3 )   562 - 567   2019.6

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    生後4ヵ月未満児は得られる採血量が少ないことから、自動輸血検査装置や試験管法では不規則抗体検査が困難である。このため、当院では検体量が試験管法の約1/4と少量の検体で検査可能なMicro Typing Systemを採用している。2007年1月から2016年12月までの10年間においてMicro Typing Systemでは不規則抗体検査依頼のあった生後4ヵ月未満児554件中、552件(99.6%)で検査可能であった。症例の内訳では55.4%が先天性心疾患の症例であった。また、検査可能であった552件中、不規則抗体が16件(2.9%)で陽性判定であった。そのうちの14件は母親からの移行抗体、1件は移行抗体が疑われた抗E、1件は自然抗体と考えられるIgM型の抗Mであった。さらに実際に358件に赤血球輸血が実施され、その内230件(64.2%)に輸血後の不規則抗体検査が行われたが、輸血後に生後4ヵ月未満児が不規則抗体を産生した症例は認められなかった。ほぼ全例に不規則抗体スクリーニング検査を可能とするMicro Typing Systemは乳児への輸血療法の安全性確保の観点において有用である。(著者抄録)

    researchmap

  • SOCS3 Deficiency on a High-Fat Diet Accelerates Systemic Inflammation and Results in Lethal Myeloid Hematopoiesis without Obesity and Adiposity

    Kaori Cho, Takashi Ushiki, Hajime Ishiguro, Takayuki Katagiri, Tatsuya Suwabe, Hideyo Hirai, Yoshimi Nakagawa, Masayoshi Masuko, Warren Alexander, Hitoshi Shimano, Hirohito Sone

    DIABETES   68   2019.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER DIABETES ASSOC  

    DOI: 10.2337/db19-1910-P

    Web of Science

    researchmap

  • INTENSIVE ORAL CARE CAN REDUCE BLOOD STREAM INFECTION POST NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC HSCT

    Suwabe T, Fuse K, Katsura K, Tanaka K, Tamura S, Katairi T, Tanaka T, Ushiki T, Shibasaki Y, Narita M, Sone H, Masuko M

    The 24th EHA (European Hematology Association) Congress   2019.6

     More details

  • 慢性活動性EBウイルス感染症(CAEBV)に対して同種造血幹細胞移植を施行し寛解を得た1例

    武田 ルイ, 片桐 隆幸, 河本 啓介, 難波 亜矢子, 牛木 隆志, 柴崎 康彦, 増子 正義, 瀧澤 淳, 曽根 博仁

    第144回日本内科学会信越地方会   2019.6

     More details

  • MARKER CHROMOSOME IS A STRONG POOR PROGNOSIS FACTOR AFTER ALLOGENEIC HSCT FOR AML PATIENTS

    Fuse K, Tanaka T, Uemura S, Tamura S, Suwabe T, Katagiri T, Ushiki T, Shibasaki Y, Satou N, Yano T, Kuroha T, Hashimoto S, Furukawa T, Narita M, Sone H, Masuko M

    The 24th EHA (European Hematology Association) Congress   2019.6

     More details

  • 非寛解期末梢血幹細胞移植後に通常量5‐AZA療法を施行し,寛解を維持しているEVI‐1陽性AMLの一例

    田村秀, 柴崎康彦, 上村駿, 笠見卓哉, 海發茜, 今西明, 片桐隆幸, 難波亜矢子, 河本啓介, 牛木隆志, 布施香子, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   296   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 3度目の同種造血細胞移植後ポナチニブ維持療法を行い,寛解を維持している再発・難治Ph陽性ALL

    海發茜, 柴崎康彦, 諏訪部達也, 笠見卓哉, 田村秀, 片桐隆幸, 河本啓介, 難波亜矢子, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   41st   173   2019.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 骨膜シートの骨再生機序における骨髄由来細胞の役割

    上松晃也, 牛木隆志, 石黒創, 永田昌毅, 川瀬知之, 中田光

    日本再生医療学会総会(Web)   18th   ROMBUNNO.O‐11‐3 (WEB ONLY)   2019

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 当院における再生医療新法施行前後における取り扱い細胞ソースの変化

    藤本 陽子, 渡辺 真理, 青木 寿成, 佐藤 美里, 上村 正己, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   64 ( 6 )   822 - 822   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

    Kyoko Fuse, Tomoyuki Tanaka, Shun Uemura, Tatsuya Suwabe, Takayuki Katagiri, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tastuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-113251

    Web of Science

    researchmap

  • Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

    Tatsuya Suwabe, Kyoko Fuse, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-115844

    Web of Science

    researchmap

  • Distinct Effects of Chondroitin Sulfate on Hematopoietic Cells and the Stromal Microenvironment in Bone Marrow Hematopoiesis

    Takayuki Katagiri, Takashi Ushiki, Asami Kawasaki, Shun Uemura, Tatsuya Suwabe, Tomoyuki Tanaka, Kyoko Fuse, Yasuhiko Shibasaki, Hirohito Sone, Michihiro Igarashi, Masayoshi Masuko

    BLOOD   132   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood-2018-99-115796

    Web of Science

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1678 - 1678   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 同種造血幹細胞移植における強化口腔ケアは生着後の血流感染を減少させる(Intensive oral care can reduce blood stream infection post neutrophil engraftment in allogeneic HCT)

    諏訪部 達也, 布施 香子, 勝良 剛詞, 田中 恵子, 片桐 隆幸, 田中 智之, 牛木 隆志, 柴崎 康彦, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1536 - 1536   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 単一施設におけるATGとPTCYを用いた半合致移植の後方視解析(Clinical analysis of haploidentical transplantation using ATG and PTCY in single institute)

    田中 智之, 上村 駿, 海發 茜, 田村 秀, 諏訪部 達也, 片桐 隆幸, 河本 啓介, 布施 香子, 牛木 隆志, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   59 ( 9 )   1678 - 1678   2018.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Genetically Reduced Chondroitin Sulfate Prevents the Progression of Diabetic Neuropathy

    Hajime Ishiguro, Takashi Ushiki, Asami Kawasaki, Kaori Cho, Masayoshi Masuko, Kazunori Sango, Michihiro Igarashi, Hirohito Sone

    DIABETES   67   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER DIABETES ASSOC  

    DOI: 10.2337/db18-547-P

    Web of Science

    researchmap

  • 連続的なアルブミン、血液製剤適正使用対策がもたらしたアルブミン削減効果 新潟大学医歯学総合病院における取り組み

    上村 正巳, 青木 寿成, 佐藤 美里, 大木 直江, 渡部 もも, 川合 綾野, 渡邉 苗実, 増子 正義, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   64 ( 2 )   341 - 341   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 新生児と乳児における輸血前検査の現状と課題 Micro Typing Systemを用いた生後4ヵ月以内乳児不規則抗体検査の役割と意義

    上村 正巳, 牛木 隆志

    日本輸血細胞治療学会誌   64 ( 2 )   244 - 244   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • コンドロイチン硫酸減少を介した糖尿病性神経障害の抑制効果

    石黒 創, 牛木 隆志, 河嵜 麻実, 張 かおり, 増子 正義, 三五 一憲, 五十嵐 道弘, 曽根 博仁

    糖尿病   61 ( Suppl.1 )   S - 240   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • 新潟大学医歯学総合病院における輸血関連情報カードの運用と新潟県合同輸血療法委員会を介した普及の試み

    佐藤 美里, 上村 正巳, 青木 寿成, 渡部 もも, 大木 直江, 見邉 典子, 木島 貴志, 高橋 一哲, 関 義信, 中田 光, 牛木 隆志, 新潟県合同輸血療法委員会

    日本輸血細胞治療学会誌   64 ( 2 )   428 - 428   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 急性溶血発作を来したRhnull症候群

    上村 正巳, 笠井 恵美子, 小堺 貴司, 北嶋 俊樹, 田中 智之, 増子 正義, 中田 光, 布施 一郎, 牛木 隆志

    日本輸血細胞治療学会誌   64 ( 2 )   362 - 362   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • コンドロイチン硫酸減少を介した糖尿病性神経障害の抑制効果

    石黒 創, 牛木 隆志, 河嵜 麻実, 張 かおり, 増子 正義, 三五 一憲, 五十嵐 道弘, 曽根 博仁

    糖尿病   61 ( Suppl.1 )   S - 240   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Tissue-engineered human osteogenic periosteal sheets recruit bone marrow stem cells to their implantation sites

    Uematsu K, Ishiguro H, Ushiki T, Nagata M, Nakata K, Kawase T

    Academy of Osseointegration 2018 Annual meeting   2018.2

     More details

  • 基礎研究の観点からの血漿交換回避プロトコルの妥当性

    田崎正行, 齋藤和英, 中川由紀, 佐藤隆, 舘野浩章, 牛木隆志, 高橋公太, 冨田善彦

    日本臨床腎移植学会プログラム・抄録集   51st   99   2018

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 骨膜シートは移植局所に骨髄由来造血細胞を動員する

    上松晃也, 石黒創, 牛木隆志, 永田昌毅, 星名秀行, 今井秀明, 中田光, 川瀬知之

    日本再生医療学会総会(Web)   17th   ROMBUNNO.O‐39‐6 (WEB ONLY)   2018

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ヒト下顎骨分散骨膜細胞のゼノフリー骨分化誘導試験

    伊藤祐子, 米山奈保, 牛木隆志, 川瀬知之, 中田光, 對比地久義, 伊藤彰, 中村孝人

    日本再生医療学会総会(Web)   17th   ROMBUNNO.P‐02‐076 (WEB ONLY)   2018

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • マーカー染色体が急性骨髄性白血病に対する同種造血細胞移植成績に与える影響

    田中智之, 布施香子, 諏訪部達也, 笠見卓哉, 河本啓介, 河本啓介, 牛木隆志, 森山雅人, 柴崎康彦, 柴崎康彦, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   239   2017.12

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 血小板凝集能低下により止血が困難であった骨髄異形成症候群

    田中 智之, 小堺 貴司, 北嶋 俊樹, 布施 香子, 小林 弘典, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 曽根 博仁, 布施 一郎, 増子 正義

    臨床血液   58 ( 12 )   2402 - 2405   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は75歳の女性。血液検査で貧血と末梢血に芽球を認められたため、当院を紹介受診した。骨髄穿刺で骨髄異形成症候群(myelodysplastic syndrome with excess blasts 2, MDS-EB-2)と診断された。血球減少の進行や芽球の増加、および出血症状はなく経過していた。診断から10ヵ月後、左手母指球に外傷を負い、内出血が持続し、止血困難となったため緊急入院した。血小板数は正常範囲であったが、血小板機能検査でコラーゲン凝集能とアラキドン酸凝集能の低下を認められた。抗血小板薬の内服はなく、またこれまで出血傾向の既往もなかったことから、MDSによる二次性の血小板機能低下による出血と判断し、血小板輸血を行い止血した。MDSの患者では、潜在的に血小板凝集能が低下していることが多く、血小板数の割に出血傾向が強い場合には血小板凝集能を調べ、血小板輸血などの治療介入を検討する必要がある。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J01540&link_issn=&doc_id=20180112380008&doc_link_id=130006308822&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130006308822&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • 認定再生医療等委員会運営に関わる輸血部門の役割 新潟大学医歯学総合病院における細胞治療管理体制と輸血部技師が細胞治療運用に及ぼす役割

    牛木 隆志

    日本輸血細胞治療学会誌   63 ( 6 )   814 - 814   2017.12

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Further Prognostic Factors for Stratification of Patients in the High-Risk HCT-CI Group Undergoing Allogeneic HCT

    Yasuhiko Shibasaki, Tatsuya Suwabe, Shun Uemura, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

    Kyoko Fuse, Shun Uemura, Tatsuya Suwabe, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Yasuhiko Shibasaki, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Tastuo Furukawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   130   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • TKI時代においてフィラデルフィア染色体陽性は移植後の予後不良因子ではない

    上村駿, 布施香子, 片桐隆幸, 田中智之, 小林弘典, 牛木隆志, 柴崎康彦, 成田美和子, 曽根博仁, 増子正義

    第79回日本血液学会総会   2017.10

     More details

  • 移植前予後予測モデルとしての同種造血細胞移植特異的Glasgow Prognostic Score

    柴崎康彦, 諏訪部達也, 片桐隆幸, 田中智之, 小林弘典, 布施香子, 牛木隆志, 成田美和子, 曽根博仁, 増子正義

    第79回日本血液学会総会   2017.10

     More details

  • 臍帯血移植後著明な肝萎縮と治療抵抗性腹水を合併したAITLの一例

    小堺貴司, 柴崎康彦, 田村秀, 牛木隆志, 布施香子, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    第79回日本血液学会総会   2017.10

     More details

  • 臍帯血移植後にヒトパルボウイルスB19感染による自己免疫性溶血性貧血と赤芽球癆を発症した1例

    海發 茜, 柴崎 康彦, 上村 駿, 田村 秀, 小堺 貴司, 難波 亜矢子, 小林 弘典, 布施 香子, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 8 )   1078 - 1078   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 単一施設における末梢性T細胞リンパ腫、非特定型の後方視的解析

    鈴木 隆晴, 河本 啓介, 田村 秀, 上村 駿, 海發 茜, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   58 ( 8 )   905 - 911   2017.8

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    1998年から2015年までに新潟大学医歯学総合病院血液内科で診断したPTCL,NOS 28例について臨床像,病理学的特徴,治療内容,予後を後方視的に解析した。性別は男性16例,女性12例で年齢中央値62.5(26〜88)歳。IPIはHIが10例,Hが9例であり高リスク群が68%を占めていた。初回治療としてCHOPまたはTHP-COP療法が12例に行われ,第三世代化学療法が9例に行われた。予後の確認ができた26例の観察期間中央値30ヵ月(範囲1〜164ヵ月)における2年OSは61%,2年PFSは44%であった。初回治療における効果がCRであった11例は5年OS 83%,5年PFS 75%であり,CRに至らなかった9例に比べ予後良好であった(p&lt;0.005)。PTCL,NOSに対する新規薬剤を用いた治療法の開発が望まれる。(著者抄録)

    researchmap

  • 不規則抗体スクリーニングにおけるCapture法の抗体検出能の検討

    渡部 もも, 上村 正巳, 青木 寿成, 佐藤 美里, 大木 直江, 増子 正義, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   63 ( 3 )   465 - 465   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 当院における細胞製品一元管理体制構築の試み

    青木 寿成, 上村 正巳, 藤本 陽子, 渡辺 真理, 佐藤 美里, 大木 直江, 増子 正義, 牛木 隆志

    日本輸血細胞治療学会誌   63 ( 3 )   484 - 484   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • Unique profile of immune reconstruction after three types of HLA-mismatched allogeneic hematopoietic cell transplantations

    Uemura S, Shibasaki Y, Katagiri T, Ito H, Tanaka T, Kobayashi H, Ushiki T, Fuse K, Narita M, Sone H, Masuko M

    The 8th JSH International Symposium   2017.5

     More details

  • 移植後長期フォローアップにおける再発の早期発見を目的とした末梢血STR法の有用性

    海發茜, 柴崎康彦, 中村岳史, 椎谷恵子, 和田玲子, 田村秀, 鈴木隆晴, 上村駿, 片桐隆幸, 根元洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   252   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 樹木構造接近法を用いた急性白血病,骨髄異形成症候群に対する造血細胞移植後の予後因子の解析

    布施香子, 上村駿, 海發茜, 鈴木隆晴, 田村秀, 片桐隆幸, 根本洋樹, 小林弘典, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   247   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植において生着後早期の免疫再構築はドナーソースや移植法により異なる

    上村駿, 柴崎康彦, 片桐隆幸, 井藤ヒロミ, 海發茜, 田村秀, 鈴木隆晴, 根本洋樹, 小林弘典, 布施香子, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   39th   237   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ヒトPlatelet‐rich fibrin抽出物を用いた異種血清を用いない間葉系幹細胞培養系の開発

    伊藤祐子, 米山奈保, 牛木隆志, 川瀬知之, 中田光, 對比地久義, 伊藤彰, 中村孝人

    再生医療   16   417   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 抗CCR4抗体併用化学療法による寛解後の臍帯血移植が奏効した成人T細胞白血病リンパ腫

    諏訪部 達也, 柴崎 康彦, 海發 茜, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   58 ( 1 )   32 - 36   2017.1

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は成人T細胞白血病/リンパ腫(ATLL)急性型の62歳男性。CHOP療法単独では治療抵抗性であったが,抗CCR4抗体mogamulizumab併用CHOP療法が奏効し寛解を得た。HLA一致血縁・非血縁ドナーが得られず,mogamulizumab最終投与後71日目に骨髄非破壊的前処置を用いた臍帯血移植を施行した。急性移植片対宿主病(GVHD)grade II(皮膚stage2)を発症したが,methylprednisolone投与により制御可能であり,移植後9ヵ月時点まで寛解を維持している。経過中,制御性T細胞(Treg)は著減したままの状態であった。同種造血幹細胞移植はATLLの根治的治療であるが,移植前にmogamulizumabを使用する際,Tregの減少による急性GVHDの発症頻度・重症度が増加する可能性が報告されている。寛解期移植を目指すためにmogamulizumabを使用せざるを得ない症例における至適なドナーソースや移植時期,GVHD予防法に関して,更なる症例の蓄積が望まれる。(著者抄録)

    J-GLOBAL

    researchmap

  • 機械学習を用いた急性白血病における造血幹細胞移植後の患者ベースの再発予測モデルと個別化治療への応用

    布施香子, 上村駿, 諏訪部達也, 片桐隆幸, 笠見卓哉, 田中智之, 難波亜矢子, 牛木隆志, 柴崎康彦, 柴崎康彦, 佐藤直子, 矢野敏雄, 黒羽高志, 橋本誠雄, 古川達雄, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   40th   2017

  • Elucidation of Tumor-Promoting Effects of Novel Adherent Immature Myeloid Cells in Tumor

    Takuya Tsubaki, Tetsuya Kadonosono, Tadashi Shiozawa, Takahiro Kuchimaru, Takashi Ushiki, Masayoshi Masuko, Shinae Kizaka-Kondoh

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.3690.3690

    Web of Science

    researchmap

  • Evaluation of Liver Iron Deposition in Transfusion-Dependent Patients By Dual-Energy CT

    Hironori Kobayashi, Norihiko Yoshimura, Takayuki Katagiri, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.3619.3619

    Web of Science

    researchmap

  • The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

    Kyoko Fuse, Takayuki Katagiri, Yasuhiko Shibasaki, Tomoyuki Tanaka, Miwako Narita, Hirohito Sone, Masayoshi Masuko, Tatsuo Furukawa, Naoko Sato, Toshio Yano, Takashi Kuroha, Shigeo Hashimoto, Takashi Ushiki

    BLOOD   128 ( 22 )   2016.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    0

    DOI: 10.1182/blood.V128.22.2297.2297

    Web of Science

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 当科におけるPTCL、NOS 28例の臨床病理学的解析

    鈴木 隆晴, 田村 秀, 上村 俊, 海發 茜, 河本 啓介, 根本 洋樹, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 青木 定夫, 中村 直哉, 大島 孝一, 瀧澤 淳

    臨床血液   57 ( 11 )   2426 - 2426   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 扁桃・リンパ節に多発性myeloid sarcomaを生じたMDSの1例

    片桐 隆幸, 牛木 隆志, 田中 智之, 宮腰 淑子, 難波 亜矢子, 河本 啓介, 柴崎 康彦, 瀧澤 淳, 成田 美和子, 曽根 博仁, 青木 定夫, 増子 正義

    臨床血液   57 ( 11 )   2415 - 2415   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 輸血依存患者における肝臓内鉄含有量を評価するための二重エネルギーCTの重要性(Significance of dual-energy CT to evaluate liver iron content in transfusion-dependent patients)

    Kobayashi Hironori, Yoshimura Norihiko, Suwabe Tatsuya, Katagiri Takayuki, Miyakoshi Shukuko, Ushiki Takashi, Fuse Kyoko, Shibasaki Yasuhiko, Moriyama Masato, Takizawa Jun, Narita Miwako, Sone Hirohito, Masuko Masayoshi

    臨床血液   57 ( 9 )   1524 - 1524   2016.10

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The predictive factors of favorable prognosis after allo-HSCT to refractory acute leukemia

    布施香子, 柴崎康彦, 片桐隆幸, 小林弘典, 牛木隆志, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    第76回日本血液学会総会   2016.10

     More details

  • Retrospective analysis of AITL in Niigata University Medical and Dental Hospital

    田村秀, 鈴木隆晴, 上村駿, 海發茜, 根本洋樹, 笠見卓哉, 河本啓介, 小林弘典, 牛木隆志, 布施香子, 柴崎康彦, 森山雅人, 増子正義, 成田美和子, 曽根博仁, 瀧澤淳, 中村直哉, 大島孝一

    第76回日本血液学会総会   2016.10

     More details

  • SOCS1 and SOCS3 work coordinately in inflammation by affecting cell differentiation

    Ushiki T, Roberts A, Alexander W

    第76回日本血液学会総会   2016.10

     More details

  • Successful AML-type therapy switched from pre-phase PSL for mixed phenotype acute leukemia T/M, NOS

    上村駿, 布施香子, 柴崎康彦, 根本洋樹, 小林弘典, 牛木隆志, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    第76回日本血液学会総会   2016.10

     More details

  • 当科におけるIVLBCL 14例の臨床病理学的検討

    諏訪部 達也, 河本 啓介, 片桐 隆幸, 宮腰 淑子, 小林 弘典, 牛木 隆志, 布施 香子, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 中村 直哉, 大島 孝一

    日本リンパ網内系学会会誌   56   92 - 92   2016.8

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • 抗CCR4抗体併用化学療法により寛解が得られた後に、臍帯血移植を行ったATLLの1例

    諏訪部 達也, 柴崎 康彦, 片桐 隆幸, 宮腰 淑子, 布施 香子, 小林 弘典, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 増子 正義

    臨床血液   57 ( 6 )   776 - 776   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • THE PRE-TRANSPLANT BIOMARKER RISK INDEX BASED ON SERUM FERRITIN, ALBUMIN AND CRP CAN PREDICT OUTCOMES INDEPENDENTLY OF THE HCT-CI AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

    T. Suwabe, Y. Shibasaki, T. Katagiri, S. Miyakoshi, H. Kobayashi, K. Fuse, T. Ushiki, N. Sato, T. Yano, T. Kuroha, S. Hashimoto, M. Narita, H. Sone, T. Furukawa, M. Masuko

    HAEMATOLOGICA   101   289 - 290   2016.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience

    Yasuhiko Shibasaki, Takayuki Katagiri, Hironori Kobayashi, Takashi Ushiki, Miwako Narita, Hirohito Sone, Tatsuo Furukawa, Masayoshi Masuko

    AMERICAN JOURNAL OF HEMATOLOGY   91 ( 5 )   E296 - E296   2016.5

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:WILEY  

    DOI: 10.1002/ajh.24318

    Web of Science

    researchmap

  • 当院において交差適合試験を3日間に短縮するための課題

    上村 正巳, 青木 寿成, 佐藤 美里, 大木 直江, 増子 正義, 牛木 隆志

    日本輸血細胞治療学会誌   62 ( 2 )   382 - 382   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 再生医療新法における当院輸血部の対応 臨床検査技師の経験から

    青木 寿成, 上村 正巳, 佐藤 美里, 大木 直江, 増子 正義, 牛木 隆志

    日本輸血細胞治療学会誌   62 ( 2 )   408 - 408   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • アルブミン,フェリチン,CRPを用いたBiomarker indexは,造血幹細胞移植前患者に対するHCT‐CIとは独立した予後予測因子である

    諏訪部達也, 柴崎康彦, 宮腰淑子, 布施香子, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   38th   221   2016.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • ヒトPlatelet‐rich fibrin抽出物はウシ胎児血清(FBS)の代替となり得るか?

    伊藤祐子, 川瀬知之, 牛木隆志, 中田光, 對比地久義, 伊藤彰, 中村孝人

    再生医療   15   330   2016.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Combination of Low Rate of gamma delta T Cells and High Rate of Regulatory T Cells after Allogeneic Stem Cell Transplantation Is a Poor Prognostic Factor for Patients with Hematological Neoplasm

    Yasuhiko Shibasaki, Syukuko Miyakoshi, Takayuki Katagiri, Kyoko Fuse, Hironori Kobayashi, Takashi Ushiki, Masato Moriyama, Jun Takizawa, Miwako Narita, Hirohito Sone, Masayoshi Masuko

    BLOOD   126 ( 23 )   2015.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 脳死両肺移植後の小腸DLBCL発症に対して化学療法施行後に気管支アスペルギローシスを発症した1例

    河本 啓介, 佐藤 征二郎, 根本 洋樹, 小林 弘典, 柴崎 康彦, 牛木 隆志, 森山 雅人, 瀧澤 淳, 成田 美和子, 土田 正則, 曽根 博仁, 増子 正義

    臨床血液   56 ( 11 )   2361 - 2361   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Possible involvement of lung cells harboring an abnormal karyotype in the pathogenesis of pulmonary alveolar proteinosis associated with myelodysplastic syndrome

    Masato Moriyama, Toshio Yano, Tatsuo Furukawa, Toshinori Takada, Takashi Ushiki, Masayoshi Masuko, Jun Takizawa, Hirohito Sone, Ryushi Tazawa, Yasuo Saijo, Haruyuki Ishii, Koh Nakata

    Annals of the American Thoracic Society   12 ( 8 )   1251 - 1253   2015.8

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:American Thoracic Society  

    DOI: 10.1513/AnnalsATS.201503-175LE

    Scopus

    PubMed

    researchmap

  • MYC転座とBCL2転座を認めたCD20陰性EBV陽性胃原発B細胞リンパ腫の一例

    笠見卓哉, 根本洋樹, 片桐隆幸, 河本啓介, 小林弘典, 牛木隆志, 柴崎康彦, 森山雅人, 増子正義, 成田美和子, 曽根博仁, 瀧澤淳, 橋口俊洋, 栗田大輔, 大島孝一

    第55回日本リンパ網内系学会総会   2015.7

     More details

  • 血液型抗原減弱例における血液型判定法の検討 骨髄異形成症候群による血液型抗原減弱と考えた5症例の考察

    青木 寿成, 上村 正巳, 佐藤 美里, 大木 直江, 増子 正義, 牛木 隆志

    日本輸血細胞治療学会誌   61 ( 3 )   454 - 454   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 再発時CCND1転座陽性となったCD5陽性MALTリンパ腫の1例

    根本 洋樹, 笠見 卓哉, 片桐 隆幸, 河本 啓介, 小林 弘典, 牛木 隆志, 柴崎 康彦, 森山 雅人, 増子 正義, 成田 美和子, 曽根 博仁, 瀧澤 淳, 大湊 絢, 張 大行, 尾山 徳秀, 福地 健郎, 竹内 賢吾, 中村 直哉, 栗田 大輔, 市川 理子, 大島 孝一

    日本リンパ網内系学会会誌   55   104 - 104   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    researchmap

  • USEFULNESS OF DUAL-ENERGY CT FOR DETECTION OF LIVER IRON DEPOSITION IN TRANSFUSION-DEPENDENT PATIENTS

    H. Kobayashi, N. Yoshimura, T. Kasami, T. Katagiri, H. Nemoto, K. Kawamoto, T. Ushiki, Y. Shibasaki, M. Moriyama, J. Takizawa, M. Narita, H. Sone, M. Masuko

    HAEMATOLOGICA   100   789 - 789   2015.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • PERIPHERAL BLOOD EOSINOPHIL COUNT AT DAY 28 AS A PROGNOSTIC INDICATOR IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

    K. Kawamoto, Y. Shibasaki, H. Kobayashi, T. Ushiki, N. Sato, T. Yano, M. Moriyama, T. Kuroha, J. Takizawa, S. Hashimoto, M. Narita, T. Furukawa, H. Sone, M. Masuko

    HAEMATOLOGICA   100   280 - 280   2015.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • PNH型赤血球の出現を合併したEvans症候群の1例

    小林 弘典, 笠見 卓哉, 片桐 隆幸, 根本 洋樹, 河本 啓介, 牛木 隆志, 柴崎 康彦, 森山 雅人, 瀧澤 淳, 成田 美和子, 曽根 博仁, 亀崎 豊実, 増子 正義

    臨床血液   56 ( 5 )   550 - 551   2015.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • The clinical relevance of MDS Transplantation Risk Index in allogeneic hematopoietic stem cell transplantation for patents

    Katagiri T, Shibasaki Y, Kobayashi H, Ushiki T, Sato N, Yano T, Moriyama M, Kuroha T, Takizawa J, Hashimoto M, Narita M, Sone H, Furukawa T, Masuko M

    第6回日本血液学会(JSH)国際シンポジウム   2015.5

     More details

  • 大学病院における他職種連携によるアルブミン査定減少の取り組み

    佐藤 美里, 堀田 哲夫, 若井 俊文, 田澤 由紀子, 青山 孝明, 青木 寿成, 名村 理, 古谷 健太, 小林 晴男, 増子 正義, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   61 ( 2 )   262 - 262   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 妊娠を契機に診断されたUpshaw-Schulman症候群症例における第二子妊娠の周産期管理

    森山 雅人, 玉木 悦子, 松本 雅則, 石西 綾美, 松本 吉史, 冨永 麻理恵, 工藤 理沙, 安達 聡介, 生野 寿史, 高桑 好一, 宮腰 淑子, 小堺 貴司, 小林 弘典, 牛木 隆志, 柴崎 康彦, 増子 正義, 瀧澤 淳, 成田 美和子, 曽根 博仁, 西條 康夫

    日本血栓止血学会誌   26 ( 2 )   193 - 193   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本血栓止血学会  

    researchmap

  • 不規則抗体スクリーニング検査より酵素法を省略したことによる影響の検証

    上村 正巳, 青木 寿成, 佐藤 美里, 大木 直江, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   61 ( 2 )   314 - 314   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 新潟大学医歯学総合病院でのABO血液型抗原減弱例の調査報告

    青木 寿成, 上村 正巳, 佐藤 美里, 大木 直江, 増子 正義, 中田 光, 牛木 隆志

    日本輸血細胞治療学会誌   61 ( 2 )   273 - 273   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • MDSに対する同種移植によるMDS transplant risk indexの有用性

    片桐隆幸, 柴崎康彦, 小林弘典, 牛木隆志, 佐藤直子, 矢野敏雄, 森山雅人, 黒羽高志, 瀧澤淳, 橋本誠雄, 小池正, 曽根博仁, 古川達雄, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   237   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 臍帯血移植後,血漿HHV‐6DNA量が比較的低値でありながらHHV‐6脳炎を発症したEBウイルス関連リンパ増殖症(EBV‐LPD)の一例

    根本洋樹, 小林弘典, 笠見卓哉, 片桐隆幸, 河本啓介, 牛木隆志, 柴崎康彦, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義, 石原智彦, 西澤正豊

    日本造血細胞移植学会総会プログラム・抄録集   37th   306   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 同種造血幹細胞移植における血清蛋白と発熱・炎症反応との関連性の検討

    森山雅人, 柴崎康彦, 増子正義, 根本洋樹, 片桐隆幸, 笠見卓哉, 河本啓介, 田中智之, 宮腰淑子, 小堺貴司, 小林弘典, 布施香子, 牛木隆志, 瀧澤淳, 曽根博仁, 西條康夫

    日本造血細胞移植学会総会プログラム・抄録集   37th   309   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 造血幹細胞移植後28日目の末梢血好酸球数50/μl未満は予後不良因子である

    河本啓介, 柴崎康彦, 小林弘典, 牛木隆志, 森山雅人, 瀧澤淳, 成田美和子, 曽根博仁, 増子正義

    日本造血細胞移植学会総会プログラム・抄録集   37th   230   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 骨膜シート調製における無血清培養に関する基礎的研究

    渡辺真理, 藤本陽子, 牛木隆志, 川瀬知之, 奥田一博, 永田昌毅, 伊藤彰, 吉江弘正, 中田光

    再生医療   14   308   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Clinical value of methods of adjusting DLCO forHb on the HCT-CI

    Shibasaki Y, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

    第76回日本血液学会総会   2014.10

     More details

  • Imaging of iron deposition in liver using a dual energy CT technique

    Kobayashi H, Yoshimura N, Ushiki T, Shibasaki Y, Moriyama M, Takizawa J, Narita M, Sone H, Masuko M

    第76回日本血液学会学術集会   2014.10

     More details

  • A cross-sectional study of anemia in a large cohort of apparently healthy Japanese men and women

    Nanba A, Heianza Y, Shibasaki Y, Kobayashi H, Ushiki T, Moriyama M, Takizawa J, Narita M, Tsuji H, Arase Y, Masuko M, Sone H

    第76回日本血液学会学術集会   2014.10

     More details

  • 手術室におけるヒドロキシエチルデンプン製剤とアルブミン製剤の使用実態調査

    中澤香子, 吉野太朗, 牛木隆志, 三澤昭彦, 荒川圭子, 外山聡, 佐藤博

    日本医療薬学会年会講演要旨集   24th   308 - 308   2014.8

     More details

  • 骨髄原発composite lymphoma の1例

    坪谷隆介, 小林弘典, 柴崎康彦, 牛木隆志, 森山雅人, 増子正義, 滝澤淳, 成田美和子, 曽根博仁

    第134回日本内科学会信越地方会   2014.6

     More details

  • THE ASSOCIATION OF REDUCTION OF WT1 TRANSCRIPTS IN BONE MARROW AND OUTCOMES IN ACUTE MYELOID LEUKEMIA PATIENTS

    Y. Shibasaki, T. Tanaka, S. Miyakoshi, K. Fuse, T. Kozakai, H. Kobayashi, T. Ushiki, M. Moriyama, J. Takizawa, M. Narita, M. Takahashi, H. Sone, M. Masuko

    HAEMATOLOGICA   99   565 - 566   2014.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • SOCS3ノックアウトはSOCS1ノックアウトによる慢性炎症を重症化する

    牛木 隆志, 曽根 博仁, 中田 光, Andrew Roberts, Warren Alexander

    日本臨床分子医学会学術総会プログラム・抄録集   51回   99 - 99   2014.4

     More details

    Language:Japanese   Publisher:日本臨床分子医学会  

    researchmap

  • Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients

    Masayoshi Masuko, Tatsuo Furukawa, Tadashi Koike, Kazue Takai, Koichi Nagai, Kenji Kishi, Yoshinobu Seki, Hoyu Takahashi, Sadao Aoki, Takashi Kozakai, Yasuhiko Shibasaki, Takashi Ushiki, Ken Toba, Miwako Narita, Masuhiro Takahashi, Hirohito Sone, Akira Shibata

    BLOOD   122 ( 21 )   2013.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    DOI: 10.1182/blood.V122.21.2744.2744

    Web of Science

    researchmap

  • INHIBITION OF ERYTHROPOIESIS THROUGH HEPCIDIN AND ROS IN TRANSFUSION-RELATED IRON OVERLOAD MICE

    M. Masuko, H. Kobayashi, T. Ushiki, T. Kozakai, G. Hasegawa, H. Hanawa, T. Furukawa, H. Sone, M. Naito

    HAEMATOLOGICA   98   417 - 418   2013.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:FERRATA STORTI FOUNDATION  

    Web of Science

    researchmap

  • 急性骨髄性白血病治療中にたこつぼ型心筋症を発症し、心原性ショックを来した1例

    石川 裕也, 牛木 隆志, 新國 公司, 高井 和江, 保坂 幸男

    新潟市民病院医誌   33 ( 1 )   81 - 81   2012.9

     More details

    Language:Japanese   Publisher:新潟市民病院  

    researchmap

  • AMLにおいて地固め療法後のWT1転写産物の減少は予後と関連している(Reduction value of WT1 transcripts after consolidation therapy is associated with prognosis in AML)

    Shibasaki Yasuhiko, Seki Yoshinobu, Koyama Satoru, Nikkuni Koji, Nomoto Nobuhiko, Isahai Noriatsu, Kuroha Takashi, Momoi Akihito, Yano Toshio, Ida Tori, Higashimura Masutaka, Kitajima Toshiki, Nanba Ayako, Kobayashi Hironori, Ushiki Takashi, Moriyama Masato, Okazuka Kiyoshi, Masuko Masayoshi, Toba Ken, Furukawa Tasuo

    臨床血液   53 ( 9 )   1179 - 1179   2012.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 血液悪性腫瘍患者における真菌感染症に対するvoriconazoleの有効性と安全性(Efficacy and safety of Voriconazole on fungal infections in patients with hematological malignancies)

    Miyakoshi Shukuko, Takizawa Jun, Seki Yoshinobu, Maruyama Souichi, Karimata Kaori, Kobayashi Hironori, Ida Tori, Momoi Akihito, Yano Toshio, Kuroha Takashi, Ushiki Takashi, Nikkuni Koji, Nomoto Nobuhiko, Nagai Koichi, Aoki Sadao

    臨床血液   53 ( 9 )   1092 - 1092   2012.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 自己免疫性肝炎による門脈圧亢進症症例にall-trans-retinoic acidが有効であった急性前骨髄球性白血病

    牛木 隆志, 新國 公司, 吉田 千絵, 柴崎 康彦, 石川 達, 増子 正義, 高井 和江

    臨床血液   53 ( 1 )   97 - 104   2012.1

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は35歳男性。口腔内出血で来院し,急性前骨髄球性白血病と診断された。all-trans-retinoic acid(ATRA)を併用した寛解導入療法を行い,PCR法にてPML/RARA fusion geneの分子遺伝学的寛解状態が確認されたが,長期の血球回復不全,大量腹水,腎機能障害が出現した。CTにて肝表の凹凸不整を認め,肝生検により自己免疫性肝炎及び門脈圧亢進症と診断した。肝予備能が良好であり地固め療法2コース行ったが門脈圧亢進症による汎血球減少のため地固め療法の継続が不可能と判断し,ATRAによる維持療法(45mg/m2,day1〜14)8コースへ移行した。その後,門脈圧亢進症の増悪は認めず,5年間寛解を維持している。本例は門脈圧亢進症を有する症例においてATRAが長期にわたり使用可能であることを示唆する。(著者抄録)

    researchmap

  • 寛解導入療法中にたこつぼ型心筋症を発症し、心原性ショックを来した急性骨髄性白血病

    牛木 隆志, 新國 公司, 石川 裕也, 柴崎 康彦, 保坂 幸男, 増子 正義, 高井 和江

    臨床血液   52 ( 12 )   1896 - 1899   2011.12

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    61歳男。近医にて汎血球減少を認め、急性白血病の疑いで当科に入院した。acute myeloid leukemia with myelodysplasia-related changesと診断し、Daunorubicin+Cytarabineにて完解導入療法を開始した。中心静脈カテーテル局所感染に対しMEPM+VCMの投与を行ったが、発熱が持続し血小板輸血不応となり抗HLA抗体が検出された。Pseudomonous AeruginosaおよびStaphylococcus Epidermidisが検出され、薬剤感受性によりCPFX+CLDM+VCMに変更した。SpO2が低下したため、酸素を開始したが歩行時に喘鳴が発現し、全身チアノーゼが出現し、意識混濁状態のためICU管理とした。両肺に広範な浸潤影と右葉間胸水を認め急性心不全と考えられた。心電図ではV1-V3誘導にかけ異常Q波を伴うST上昇が認められ、心臓超音波検査では心基部以外はakinesisの状態で、たこつぼ型心筋症として典型的所見であった。フロセミド静注したところ突然に収縮期血圧が低下したが、抗HLA抗体陽性であり侵襲的処置は困難であった。ノルアドレナリンを併用し、ドパミンのフラッシュを繰り返した。感染症の合併を否定できず、CPFX+CLDM+LZD+VRCZ+GCV+Pentamidine+IVIG投与を開始し、最終的にドパミン10γ+ノルアドレナリン0.1γ+アドレナリン0.05γを維持量とし、昇圧剤を漸減しday33にICUを退室した。High-dose cytarabineにて施行した地固め療法ではEFは開始時にはほぼ正常化し2コース終了以後、たこつぼ型心筋症の再燃は認めていない。

    researchmap

  • 小児の発作性寒冷血色素尿症の2症例 輸血経過とDonath-Landsteiner抗体の抗原特異性について

    伊藤 京子, 小南 真由美, 鈴木 典子, 志田 幸江, 常山 初江, 高井 和江, 斉藤 治重, 新國 公司, 牛木 隆志

    日本輸血細胞治療学会誌   57 ( 2 )   267 - 267   2011.3

     More details

    Language:Japanese   Publisher:(一社)日本輸血・細胞治療学会  

    researchmap

  • 骨髄に少数のPh染色体陽性細胞を認めた非定型的骨髄増殖性腫瘍

    高井 和江, 牛木 隆志, 新國 公司, 橋立 英樹, 渋谷 宏行

    臨床血液   52 ( 2 )   73 - 77   2011.2

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    症例は52歳の女性。2003年1月から高度の血小板増加を認め,本態性血小板血症の疑いで経過観察中に,貧血,白血球減少が出現し,2007年11月当院を受診した。骨髄生検で巨核球増加と骨髄線維化を認めたが脾腫を認めず。骨髄染色体分析で,t(9;22)(q34;q11.2)を6/20細胞に認めたが,末梢血好中球BCR-ABL(FISH)融合シグナルは正常範囲内であった。骨髄液のRT-PCR法でM-BCR/ABL mRNA(b3a2型)を認め,2008年5月からimatinib400mg内服を開始した。一過性の血小板減少後末梢血は正常化し,骨髄線維症も軽快傾向にある。なお,末梢血でJAK2 V617F変異は陰性,M-BCR-ABL mRNA(TMA)は検出感度以下である。考察:経過中好中球増加がみられず,好中球にBCR-ABL融合遺伝子を認めないこと,imatinibにより骨髄巨核球の減少と線維化が改善したことから,BCR-ABL転座が主として巨核球系細胞に発現した極めてまれな骨髄増殖性腫瘍と考えられる。(著者抄録)

    researchmap

  • 近赤外蛍光を用いた骨髄移植後超早期における移植骨髄細胞の生体内動態解析

    牛木隆志

    第5回 IVIS® Imaging System ユーザー会   124 ( 7 )   366 - 376   2010.10

     More details

    Language:Japanese   Publisher:新潟医学会  

    【目的】近年のin vivo imagingの技術革新は著しく、これまで追跡困難であった骨髄移植後の造血幹細胞を体外よりイメージングすることが試みられている。In vivo imagingに基づいた造血幹細胞の生体内動態解析は、骨髄移植に関連した病態を理解する上で重要な情報である。今回、我々は細胞数が少数であるため、in vivo imagingが特に困難であった骨髄再構築前の移植ドナー細胞の細胞動態について検討した。【方法】BALB/c nu/nu(H-2d)に対し、Alexa Fluor 750により細胞外標識したドナー骨髄単核球を用いて、静注法による骨髄移植や骨髄内骨髄移植などの移植法を施行した。また、その近赤外蛍光をIVIS SPECTRUM(Xenogen)を用い、経時的に移植後24時間の観察を行った。【結果】ドナー細胞の蛍光標識に際し、細胞膜を均一に標識することで、細胞種によらず100%の標識効率が得られた。骨髄移植モデルでは脛骨へのホーミングは移植後1時間より認められ、移植後6時間まで蛍光強度は増強した。また、これまで骨髄移植後の細胞動態が不明であった骨髄内骨髄移植においてもその移植後の生体内動態を可視化することに成功した。今回考案した近赤外蛍光色素標識を用いた細胞動態解析法は、これまで病理学的手法以外に評価困難であった移植細胞の骨髄内への移行及び網内系臓器での捕捉量の変化をreal-timeで観察することが可能であり、骨髄移植の病態解明に有用な手法である。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2010&ichushi_jid=J00990&link_issn=&doc_id=20101208070002&doc_link_id=%2Fdg3nigta%2F2010%2F012407%2F002%2F0366-0376%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2010%2F012407%2F002%2F0366-0376%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 成熟顆粒球の殆どが病的芽球から分化したt(8;21)を伴うAML(AML with t(8:21) which most of mature granulocytes differentiated from pathological blast)

    Kozakai Takashi, Kobayashi Hironori, Ushiki Takashi, Kitajima Toshiki, Higashimura Masutaka, Yano Toshio, Abe Takashi, Masuko Masayoshi, Furukawa Tatsuo, Toba Ken, Aizawa Yoshifusa

    臨床血液   51 ( 9 )   1228 - 1228   2010.9

     More details

    Language:English   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation

    Takashi Ushiki

    The Walter and Eliza Hall Institute of Medical Research-Special Seminar   2010.8

     More details

  • 近赤外光プローブを用いたHIF活性細胞のIn vivoイメージング

    口丸 高弘, 門之園 哲哉, 牛木 隆志, 近藤 科江, 平岡 真寛

    JSMI Report   3 ( 2 )   152 - 152   2010.5

     More details

    Language:Japanese   Publisher:日本分子イメージング学会  

    researchmap

  • HIF活性化細胞特異的プローブの分子評価と標識蛍光色素の特性による生体イメージングの変化

    門之園 哲哉, 口丸 高弘, 牛木 隆志, 近藤 科江, 平岡 眞寛

    JSMI Report   3 ( 2 )   150 - 150   2010.5

     More details

    Language:Japanese   Publisher:日本分子イメージング学会  

    researchmap

  • HIF活性化細胞特異的プローブの分子評価と標識蛍光色素の特性による生体イメージングの変化

    門之園 哲哉, 口丸 高弘, 牛木 隆志, 近藤 科江, 平岡 眞寛

    JSMI Report   3 ( 2 )   45 - 45   2010.5

     More details

    Language:Japanese   Publisher:日本分子イメージング学会  

    researchmap

  • 慢性脳低灌流モデルにおける骨髄単核球細胞の動態と白質保護効果

    藤田 祐之, 猪原 匡史, 牛木 隆志, 近藤 科江, 伊東 秀文, 高橋 良輔

    臨床神経学   49 ( 12 )   1140 - 1140   2009.12

     More details

    Language:Japanese   Publisher:(一社)日本神経学会  

    researchmap

  • In Vivo Tracking of Hematopoietic Stem/Progenitor Cells before Hematopoietic Reconstitution in Murine Bone Marrow Transplantation Models Using Near-infrared Fluorescence Imaging

    Takashi Ushiki, Shinae Kizaka-Kondoh, Eishi Ashihara, Shotaro Tanaka, Masayoshi Masuko, Hideyo Hirai, Shinya Kimura, Taira Maekawa, Masahiro Hiraoka

    Kyoto University Global COE ''Center for Frontier Medicine'' International Synposium/Retreat 2009   2009.11

     More details

  • 近赤外蛍光色素を用いた移植骨髄細胞の生体内動態解析

    牛木 隆志, 近藤 科江, 芦原 英司, 田中 正太郎, 平位 秀世, 木村 晋也, 前川 平, 平岡 真寛

    臨床血液   50 ( 9 )   899 - 899   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • マウス造血幹細胞移植におけるIn vivo dynamic imaging

    牛木隆志, 近藤科江, 芦原英司, 田中正太郎, 木村晋也, 前川 平, 平岡真寛

    第9回文部科学省特定領域研究「がん」5領域 若手研究者ワークショップ   2009.9

     More details

  • 近赤外蛍光を用いたマウス造血幹細胞移植の骨髄再構築前における超早期イメージング

    牛木隆志, 近藤科江, 芦原英司, 田中正太郎, 平位秀世, 木村晋也, 前川 平, 平岡真寛

    第10回文部科学省特定領域研究「がん」5領域 若手研究者ワークショップ   2009.9

     More details

  • A novel approach for dynamic analysis of transplanted hematopoietic stem/progenitor cells in vivo by near-infrared fluorescence imaging

    Takashi Ushiki, Shinae Kizaka-Kondoh, Eishi Ashihara, Shotaro Tanaka, Hideyo Hirai, Shinya Kimura, Taira Maekawa, Masahiro Hiraoka

    2009 World Molecular Imaging Congress   2009.9

     More details

  • 肝性脳症に対しB-RTOが奏効した1例

    上村 博輝, 牛木 隆志, 富樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子

    新潟医学会雑誌   123 ( 8 )   434 - 435   2009.8

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 経頸静脈的肝生検吸引生検針の開発

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 石原 法子, 上村 朝輝

    新潟医学会雑誌   123 ( 8 )   429 - 429   2009.8

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • Sinusoidal T-cell lymphomaと鑑別を要したサイトメガロウイルス肝炎の1例

    牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 小山 覚, 武田 敬子, 石原 法子

    新潟医学会雑誌   123 ( 8 )   428 - 428   2009.8

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 黄疸と薬疹を伴った伝染性単核球症の1例

    牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 小山 覚, 武田 敬子, 石原 法子

    新潟医学会雑誌   123 ( 8 )   426 - 426   2009.8

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 光イメージングを用いた造血幹細胞移植への新規アプローチ

    USHIKI TAKASHI, KONDO SHINAE, ASHIHARA EISHI, TANAKA SHOTARO, HIRAI HIDEYO, KIMURA SHIN'YA, MAEKAWA TAIRA, HIRAOKA MASAHIRO

    JSMI Rep   2 ( 2 )   158   2009.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

    Miki Takeuchi, Shinya Kimura, Junya Kuroda, Takashi Ushiki, Makoto Kawatani, Hiroyuki Osada, Kazuo Umezawa, Eiko Yasui, Masaya Imoto, Takashi Tsuruo, Keiko Hodohara, Tatsutoshi Nakahata, Yoshihide Fujiyama, Taira Maekawa

    BLOOD   112 ( 11 )   1092 - 1093   2008.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models

    Ruriko Tanaka, Matthew S. Squires, Shinya Kimura, Asumi Yokota, Kirsty Mallett, Tomoko Smyth, Neil T. Thompson, Rina Nagao, Takahiro Yamauchi, Takashi Ushiki, John F. Lyons, Taira Maekawa

    BLOOD   112 ( 11 )   403 - 403   2008.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC HEMATOLOGY  

    Web of Science

    researchmap

  • 同種造血幹細胞移植後にIdiopathic Pneumonia Syndromeをきたした3例の血清サイトカインの推移

    阿部 崇, 牛木 隆志, 柴崎 康彦, 東村 益孝, 岡塚 貴世志, 黒羽 高志, 鳥羽 健, 相澤 義房, 増子 正義, 古川 達雄, 飯酒盃 訓充, 永井 孝一, 関 義信

    臨床血液   49 ( 9 )   1219 - 1219   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 光イメージングにおける餌の発光・蛍光バックグラウンドの検討

    高橋由美, 高橋由美, 加藤友久, 牛木隆志, 田中正太郎, 近藤科江

    日本実験動物学会総会講演要旨集   55th   177   2008.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Recipient由来CD8陽性T細胞の増加とともに急速に拒絶をきたした臍帯血移植例

    岡塚 貴世志, 増子 正義, 牛木 隆志, 佐藤 直子, 藤原 正博, 橋本 誠雄, 小池 正, 鳥羽 健, 古川 達雄, 相澤 義房

    臨床血液   48 ( 9 )   1101 - 1101   2007.9

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    researchmap

  • 臍帯血移植15ヵ月後に初感染による急性B型肝炎を発症し,肝機能障害が遷延した1例

    狩俣 かおり, 増子 正義, 瀧澤 淳, 牛木 隆志, 矢野 敏雄, 津端 俊介, 大越 章吾, 鳥羽 健, 古川 達雄, 相澤 義房

    第120回日本内科学会信越地方会   2007.6

     More details

  • 進行膵癌に対するGemcitabineとFP療法の比較

    太田 宏信, 牛木 隆志, 富樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 吉田 俊明, 上村 朝輝, 馬場 靖幸, 真船 善朗, 石川 直樹

    新潟医学会雑誌   121 ( 3 )   170 - 170   2007.3

     More details

    Language:Japanese   Publisher:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2007306251

  • 脾原発炎症性偽腫瘍の1例

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 武者 信行, 坪野 俊広, 酒井 靖夫, 武田 敬子, 石原 法子

    日本消化器病学会雑誌   104 ( 3 )   407 - 412   2007.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    脾炎症性偽腫瘍(inflammatory pseudotumor)の1例を経験したので報告する。症例は59歳男性、CRP持続陽性精査のため、腹部CT施行。CT検査にて脾に単純で低吸収、造影にて脾実質より相対的に低吸収となる腫瘤性病変を認めた。MRI検査ではT1強調、T2強調ともに内部に一部高信号をともなう低信号の腫瘤像を呈した。血管造影でも悪性所見に乏しく、無症状であるが、CRP上昇の原因と考え、また、悪性リンパ腫の可能性が否定しきれず治療的診断的意義を兼ねて、脾臓摘出術を施行した。病理組織学的に脾炎症性偽腫瘍と診断した。脾炎症性偽腫瘍は極めてまれであり、悪性腫瘍との鑑別診断が困難である。確定診断は術後の病理組織診断によるため、脾臓摘出が治療的意義と同時に診断的意義を有し、予後も良好である。(著者抄録)

    researchmap

  • 当科におけるT細胞性リンパ腫の治療成績

    桃井 明仁, 瀧澤 淳, 牛木 隆志, 岡塚 貴世志, 狩俣 かおり, 矢野 敏雄, 増子 正義, 鳥羽 健, 青木 定夫, 相澤 義房

    日本内科学会雑誌   96 ( Suppl. )   158 - 158   2007.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • Arterial chemotherapy for elderly patients with inoperable pancreatic cancer

    石川達, 牛木隆志, 冨樫忠之, 渡辺孝治, 関慶一, 太田宏信, 吉田俊明, 上村朝輝

    老年消化器病   18 ( 1 )   2007

  • 重症急性膵炎に伴う急性肺障害に対する好中球エラスターゼ阻害薬(sivelestat sodium)の有用性

    石川達, 牛木隆志, 今井径卓, 上村博輝, 土屋淳紀, 冨樫忠之, 渡辺孝治, 関慶一, 太田宏信, 吉田俊明, 上村朝輝

    Progress in Medicine   27 ( 2 )   409 - 412   2007

     More details

    Language:Japanese   Publisher:(株)ライフ・サイエンス  

    症例1:56歳男。心窩部痛が増悪し、ショック状態を来たした。検査所見で白血球数、amylaseなどの上昇、CTで両側傍腎腔の液体貯留などを認め、急性膵炎、Grade Vと診断し、APACHE II scoreも11点であったため、蛋白分解酵素阻害薬および抗菌薬の動注療法を行った。加療開始後改善傾向を認めたが、全身性炎症反応症候群に伴う急性肺障害を合併したため、人工呼吸管理と同時にsivelestat sodium、利尿薬、アルブミン製剤の投与を開始した。病態は改善し6日間で抜管でき、内科的治療の継続により退院となった。症例2:27歳男。腹痛が増悪し、ショック状態となった。CTで膵融解像、膵・腎周囲滲出液を認め、急性膵炎、Grade IV、APACHE II score 8点と診断し、動注療法および持続血液濾過透析を施行した。更に、PaO2/FIO2比の低下傾向を認めたため、急性呼吸窮迫症候群の危険性を考えsivelestat sodiumを併用した。その結果、早期改善を認め、発症23日で退院した。

    J-GLOBAL

    researchmap

  • 進行膵癌に対するGemcitabineとCDDP・5-FU療法の治療成績の比較検討

    太田 宏信, 牛木 隆志, 水野 研一, 富樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 吉田 俊明, 上村 朝輝, 馬場 靖幸, 真船 善朗, 石川 直樹

    癌と化学療法   33 ( 9 )   1267 - 1271   2006.9

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    gemcitabine hydrochloride(GEM)は切除不能膵癌に対する第一選択薬剤と評価されている。今回、当科におけるGEMとCDDP・5-FU療法(FP療法)の効果をretrospectiveに比較検討し、FP療法がGEMのsecond-lineになり得るか否か評価した。対象はFP群19例(II1例、III2例、IV a2例、IV b14例)とGEM群32例(IV a3例、IV b29例)。奏効率はFP群10.5%、GEM群15.6%。50%平均生存期間はFP群137日、GEM群241日で統計的有意差は認めなかったが、IV b症例に限ればGEM群で有意な延命効果が認められた。副作用ではFP群で消化器症状が強かった。今回の検討からFP療法はGEMのsecond-lineとすることは困難と思われた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2006&ichushi_jid=J00296&link_issn=&doc_id=20060925480011&doc_link_id=%2Fab8gtkrc%2F2006%2F003309%2F011%2F1267-1271%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2006%2F003309%2F011%2F1267-1271%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 上腸間膜静脈・門脈血栓症を伴うIPHと考えられた一例

    上村 博輝, 牛木 隆志, 冨樫 忠之, 渡邉 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 武者 信行, 坪野 俊広, 酒井 靖夫, 石原 法子, 武田 敬子, 上村 朝輝

    ENDOSCOPIC FORUM for digestive disease   22 ( 1 )   72 - 72   2006.6

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    researchmap

  • 黄疸と薬疹を伴った伝染性単核球症の一例

    牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子, 石原 法子

    第118回日本内科学会信越地方会   2006.5

     More details

  • Sinusoidal T-cell lymphomaと鑑別を要したサイトメガロウイルス肝炎の一例

    牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 上村 朝輝, 小山 覚, 石原 法子

    第118回日本内科学会信越地方会   2006.5

     More details

  • 胃静脈瘤に対するB-RTO後の食道静脈瘤の経過に関する検討

    石川 達, 上村 博輝, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    Gastroenterological Endoscopy   48 ( Suppl.1 )   759 - 759   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    researchmap

  • 高齢者C型慢性肝炎に対するインターフェロン療法 IFNβ先行投与症例の検討

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   47 ( Suppl.1 )   A176 - A176   2006.4

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  • 肝細胞癌に対するRITA社ハンドピースModel-90展開型RFAニードルの使用経験

    石川 達, 上村 博輝, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本内科学会雑誌   95 ( Suppl. )   174 - 174   2006.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • 食道原発悪性黒色腫の1例

    牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 武者 信行, 武田 敬子, 石原 法子, 上村 朝輝

    ENDOSCOPIC FORUM for digestive disease   21 ( 2 )   195 - 195   2005.11

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    researchmap

  • 閉塞性黄疸を来した自己免疫性膵炎の1例

    牛木 隆志, 水野 研一, 冨樫 忠之, 渡辺 孝治, 関 慶一, 石川 達, 太田 宏信, 吉田 俊明, 武田 敬子, 上村 朝輝

    第117回日本内科学会信越地方会   2005.10

     More details

  • 動注用アイエーコールによる腫瘍壊死を病理学的に確認しえた肝細胞癌切除例

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 坪野 俊広, 石原 法子, 上村 朝輝

    第117回日本内科学会信越地方会   2005.10

     More details

  • 門脈浸潤(Vp3,Vp4)を伴う進行肝細胞癌に対するmodified EEP療法の検討

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    肝臓   46 ( Suppl.2 )   A425 - A425   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

    researchmap

  • 切除不能膵癌に対する昇圧動注化学療法

    石川 達, 牛木 隆志, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本癌治療学会誌   40 ( 2 )   684 - 684   2005.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    researchmap

  • 総胆管結石を合併し診断困難であった非露出腫瘤型Vater乳頭部癌の1例

    牛木 隆志,石川 達,冨樫 忠之,渡辺 孝治,関 慶一,太田 宏信,吉田 俊明,武田 敬子,石原 法子,上村 朝輝

    第116回日本内科学会信越地方会   2005.6

     More details

  • 急性膵炎後感染性膵仮性嚢胞に対しSomatostatin analogue投与が奏効した1例

    石川 達, 牛木 隆志, 水野 研一, 冨樫 忠之, 渡辺 孝治, 関 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝

    日本内科学会雑誌   94 ( Suppl. )   126 - 126   2005.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • 関節リウマチ患者にみられた、好酸球増加を伴い縦隔腫瘍との鑑別を要した偽性乳び胸の一例

    牛木隆志, 成田淳一, 森山寛史, 寺田正樹, 高田俊範, 長谷川隆志, 塚田弘樹, 吉澤弘久, 下条文武, 青木 正, 土田正則, 鈴木栄一

    第54回日本呼吸器学会北陸地方会   2004.11

     More details

  • 集学的治療により救命し得た重症急性膵炎の1例

    牛木 隆志, 石川 達, 水野 研一, 冨樫 忠之, 渡辺 孝治, 関, 慶一, 太田 宏信, 吉田 俊明, 上村 朝輝, 武田 敬子

    第115回日本内科学会信越地方会   2004.10

     More details

  • 当科における血管内悪性リンパ腫4例の臨床的検討

    牛木 隆志, 塚田 信弘, 中村 直哉, 朝川 勝明, 阿部 崇, 黒羽 高志, 増子 正義, 瀧澤 淳, 八木沢 久美子, 橋本 誠雄, 鳥羽 健, 青木 定夫, 相澤 義房

    日本血液学会・日本臨床血液学会総会プログラム・抄録集   66回・46回   971 - 971   2004.9

     More details

    Language:Japanese   Publisher:日本臨床血液学会  

    researchmap

  • 進行性低酸素血症と不明熱で発症しintravascular large B-cell lymphoma(IVL)と診断し得た1例

    牛木 隆志, 櫛谷 幸嗣, 中山 秀章, 吉澤 弘久, 下条 文武, 真田 明子, 八木沢 久美子, 瀧澤 淳, 池滝 知, 河合 一浩

    第114回日本内科学会信越地方会   2004.5

     More details

▶ display all

Industrial property rights

  • T細胞増殖促進ペプチド

    門之園 哲哉、牛木 隆志、近藤 科江

     More details

    Applicant:国立大学法人東京工業大学、国立大学法人 新潟大学

    Application no:特願2021-97735  Date applied:2021.6

    Announcement no:特開2022-189249  Date announced:2022.12

    researchmap

Awards

  • 令和6年度 塚田医学奨学助成金

    2024.4  

    諏訪部達也、牛木隆志、増子正義

     More details

  • 第23回日本再生医療学会総会 優秀演題賞

    2024.3   日本再生医療学会  

    牛木 隆志

     More details

  • 令和4年度 学術研究助成金

    2023.4   新潟県医師会  

    石黒 創, 牛木 隆志, 五十嵐 道弘, 曽根 博仁

     More details

  • 第10回研究助成

    2021.12   公益財団法人 小林財団  

    牛木 隆志

     More details

  • 第11回学術賞(基礎系)

    2020.2   日本口腔インプラント学会 関東・甲信越支部  

    上松晃也、牛木隆志

     More details

  • ベストポスター賞

    2009.9   文部科学省 がん特定領域研究・若手研究者ワークショップ  

    牛木 隆志

     More details

  • 京都大学グローバルCOEプログラム国際学会発表派遣助成

    2009.9  

    牛木 隆志

     More details

  • World Molecular Imaging Congress Student Travel Stipend Award

    2009.9  

    牛木 隆志

     More details

▶ display all

Research Projects

  • PRP治療に影響する可能性がある血小板のミトコンドリア転移現象の検証と再現

    2024.4 - 2027.3

    System name:科学研究費助成事業 基盤研究(C)

    Awarding organization:日本学術振興会

    川瀬知之, 望月友晴, 牛木隆志

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  • 骨髄異形成症候群における腫瘍細胞特異的CTLの高感度検出法と機能増強法の開発

    2024.4 - 2026.3

    System name:科学研究費助成事業 若手研究

    Awarding organization:日本学術振興会

    諏訪部達也

      More details

    Authorship:Collaborating Investigator(s) (not designated on Grant-in-Aid) 

    researchmap

  • 骨髄系腫瘍に対する腫瘍免疫療法の確立に向けたWT1特異的CTLの検出と機能修飾法の開発

    2024.4 - 2025.3

    Awarding organization:令和6年度 塚田医学奨学助成金

    諏訪部達也, 牛木隆志, 増子正義

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  • 令和5年度 新潟大学 博士育成のための論文投稿支援プログラム

    2023.12 - 2024.3

    Awarding organization:新潟大学

    牛木隆志

      More details

  • プロアスリートの解析から見たPRP療法への応答性を決定する品質の探索:予知性向上へ

    2023.4 - 2026.3

    System name:科学研究費助成事業 基盤研究(C)

    Awarding organization:日本学術振興会

    望月 友晴、牛木 隆志、川瀬 知之、大森 豪

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  • 骨髄異形成症候群の骨髄微小環境中における腫瘍細胞特異的CTLの機能修飾法の開発

    2023.4 - 2024.3

    System name:日本血液学会2023年度研究助成

    Awarding organization:日本血液学会

    諏訪部 達也

      More details

    Authorship:Collaborating Investigator(s) (not designated on Grant-in-Aid) 

    researchmap

  • 腸管免疫を介した SOCS3 による高脂肪食誘発性 GVHD の増悪抑制効果

    2023.4 - 2024.3

    System name:日本血液学会2023年度研究助成

    Awarding organization:日本血液学会

    牛木 隆志

      More details

    Authorship:Principal investigator 

    researchmap

  • TGF-βに着目した、コンドロイチン硫酸と糖尿病性神経障害の関連の検討

    2023.4 - 2024.3

    System name:令和4年度 学術研究助成金

    Awarding organization:新潟県医師会

    石黒 創

      More details

    Authorship:Collaborating Investigator(s) (not designated on Grant-in-Aid) 

    researchmap

  • プロアスリートの組織修復能力を高める多血小板血漿治療のエビデンス創出

    2023.4

    System name:チャレンジマイル2022

    Awarding organization:新潟大学

    牛木隆志, 望月友晴, 川瀬知之

      More details

    Authorship:Principal investigator 

    researchmap

  • 令和4年度 新潟大学 博士育成のための論文投稿支援プログラム

    2022.11 - 2023.3

    Awarding organization:新潟大学(大学院医歯学総合研究科枠)

    牛木隆志

      More details

    Grant type:Competitive

    researchmap

  • アスリートに特化したPRP治療の開発:血小板ポリリン酸に注目した分析と応用

    2022.8 - 2023.3

    System name:令和4年度 新潟大学 U-goグラント (継続課題)

    牛木隆志, 望月友晴, 川瀬知之, 田中孝明

      More details

    Authorship:Principal investigator 

    researchmap

  • アスリートの選手生命を救うPRP治療の確立に向けた基盤的研究

    2022.4 - 2025.3

    System name:科学研究費助成事業 基盤研究(C)

    Awarding organization:日本学術振興会

    牛木 隆志、川瀬 知之、望月 友晴、田中 孝明

      More details

    Authorship:Principal investigator 

    researchmap

  • SOCS3を介した高脂肪食誘発性GVHDの免疫制御機構

    2022.1 - 2024.12

    System name:第10回(令和3年度)研究助成

    Awarding organization:公益財団法人 小林財団

    牛木 隆志

      More details

    Authorship:Principal investigator 

    researchmap

  • アスリートに特化したPRP治療の開発:血小板ポリリン酸に注目した分析と応用

    2021.9 - 2022.3

    System name:令和3年度 新潟大学 U-goグラント

    牛木隆志、望月友晴、川瀬知之、田中孝明

      More details

    Authorship:Principal investigator 

    researchmap

  • ABO血液型不適合腎移植における糖鎖アレイを用いた新規血液型抗体測定法の臨床応用

    2021.4 - 2024.3

    System name:日本学術振興会 科学研究費助成事業 基盤研究(C)

    田崎 正行, 齋藤 和英, 舘野 浩章, 牛木 隆志

      More details

  • SOCS3欠失マウスにおける食事誘発性炎症がGVHD重症化に及ぼす役割

    Grant number:21K11671

    2021.4 - 2024.3

    System name:日本学術振興会 科学研究費助成事業 基盤研究(C)

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    石黒 創, 牛木 隆志

      More details

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    移植片対宿主病(GVHD)は日本と欧米でその発症率に差異がある。その理由としてHLAなどの遺伝的背景以外に、食生活の違いが影響している可能性が考えられる。
    申請者らはマウスSyngenic骨髄移植モデルにおいて、サイトカインシグナル伝達阻害因子(SOCS) 3ノックアウト(KO)血球は、単独での炎症誘発作用はないが、炎症modulaterに対する強力な炎症加速作用を有する可能性を見出した。そこで実際に、homogeneousなSOCS3全身KOマウスに対し、炎症modulaterとしてhigh fat diet(HFD)を投与したところ、末梢血中の顆粒球増加と共に脾腫を来たし、致死的経過を辿った。また、肝臓、皮膚に高度の炎症細胞浸潤を来たし、その病理像には肥満にみられる典型的な病理像はなくGVHDに類似していた。
    栄養素を介した免疫変調は免疫学的なトピックでもあり、SOCS3KOマウスを用いてGVHDへの食事の影響を明らかとすることで、食事を介してGVHDの重症化を軽減することが可能となる。ひいては、造血幹細胞移植成績の向上につながる知見が得られる可能性がある。
    本年度我々は、条件検討のために、野生型のマウスを用いて数通りのGVHDモデルを作成し、コントロール食もしくは高脂肪食を投与したところ、いずれの群でも、高脂肪食投与でGVHDが重症化することが判明した。栄養成分の違い、ひいては食生活の違いが、GVHDの病態を悪化させることが示唆された。

    researchmap

  • SOCS3欠失マウスで誘発される高脂肪誘発性顆粒球増多における腸管Th17細胞の関与

    2021.4 - 2022.3

    Awarding organization:日本血液学会 日本血液学会2021年度研究助成

    牛木 隆志

      More details

    Authorship:Principal investigator 

    researchmap

  • SOCS3が制御する高脂肪誘発性myeloid hematopoiesisの造血機構

    2020.4 - 2021.3

    System name:日本血液学会2020年度研究助成

    Awarding organization:日本血液学会

    牛木 隆志

      More details

  • SOCS3が制御する高脂肪誘発性myeloid hematopoiesisの機序

    2019.4 - 2024.3

    System name:科学研究費助成事業 基盤研究(C)

    Awarding organization:日本学術振興会

    牛木 隆志

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 骨髄由来幹細胞により制御される骨膜シートの骨化機序の解明

    Grant number:19K19048

    2019.4 - 2021.3

    System name:科学研究費助成事業 若手研究

    Research category:若手研究

    Awarding organization:日本学術振興会

    上松 晃也

      More details

    Grant amount:\4030000 ( Direct Cost: \3100000 、 Indirect Cost:\930000 )

    培養人工骨:ヒト骨膜シート(Human Periosteal Sheet:以下HPS)の骨再生機序は未だ不明な点が多い。本研究では移植したヒト骨膜シートが局所に骨髄由来細胞を誘導する現象の詳細な機序を解析した。骨髄細胞のみがGFP標識されたキメラマウスを作製し、その背部皮下にHPSを移植した。8週後に摘出し組織学的に解析したところHPS周囲にGFP陽性の骨髄細胞の集積が確認できた。また血管の新生も同様に生じており、骨髄由来細胞は新生された血管を通じて骨髄より遊走してきていると推察される。上記の実験を骨分化度の高いHPSと未分化な状態に抑えられたHPSの2群で比較した。結果としては骨分化度の高いHPSにおいてより多くのGFP陽性骨髄由来細胞の集積が認められた。またマウス移植前の段階での遺伝子発現をqPCRで解析したところ、こちらも分化度の高いHPSにおいてMSCを局所に遊走させるSDF-1の発現が有意に上昇していた。これらの結果より、骨再生効果の高いHPSの培養条件としては培養段階である程度骨分化させるように調整してくことが有効であることが考えられる。しかしながら、骨髄由来細胞がHPSにより局所に動員されたのちにどのような過程により骨の組織を形成する、もしくは形成するのに寄与するのかは今後さらなる検証が必要である。

    researchmap

  • Research about the relationship between diabetic neuropathy and chondroitin sulfate

    Grant number:19K18001

    2019.4 - 2021.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Early-Career Scientists

    Awarding organization:Japan Society for the Promotion of Science

    Ishiguro Hajime

      More details

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    The involvement of chondroitin sulfate, a major extracellular matrix, has been pointed out in the development of diabetic neuropathy. However, the details are unknown. We examined using CSGalNAc T1 knockout mice (T1KO mice), which are the major synthases of chondroitin sulfate. The progression of diabetic neuropathy was suppressed in these T1KO mice. It was suggested that the mechanism is deeply related to cells called pericytes around blood vessels, which express chondroitin sulfate.
    Currently, we are continuing the research to elucidate the mechanism.

    researchmap

  • SOCS3が腸内細菌叢を介して制御する高脂肪誘発性myeloid hematopoiesisの機序

    2019.4 - 2020.3

    System name:日本血液学会2019年度研究助成

    Awarding organization:日本血液学会

    牛木 隆志

      More details

  • 重症GVHD治療に向けたCD25中和抗体代替ペプチド製剤の開発

    2018.4 - 2020.3

    System name:創薬基盤推進研究事業

    Awarding organization:日本医療研究開発機構(AMED)

    門之園 哲哉, 牛木 隆志

      More details

    Grant type:Competitive

    researchmap

  • SOCS3を介したメタボリックシンドロームにおける炎症細胞浸潤の抑制効果

    2018.4 - 2019.3

    System name:日本血液学会平成30年度研究助成

    Awarding organization:日本血液学会

    牛木 隆志

      More details

  • Development of glycoconjugate microarray for the prediction of antibody mediated rejection in ABO incompatible kidney transplant

    Grant number:17K11195

    2017.4 - 2020.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    Tasaki Masayuki

      More details

    Grant type:Competitive

    Grant amount:\4550000 ( Direct Cost: \3500000 、 Indirect Cost:\1050000 )

    It is important to examine about antibody titer against donor ABO blood group antigen before ABO-incompatible kidney transplantation in order to control acute antibody mediated rejection. However, the results of existing method using red blood cells is not often corelated to clinical outcomes. In the present study, we developed the novel method to examine antibody titer against ABO blood group antigens specifically expressed on kidney endothelial cells. This method showed significant predictive value of acute antibody mediated rejection after ABO-incompatible kidney transplantation.

    researchmap

  • 輸血関連情報提供カード作成プロジェクト

    2017.4 - 2018.3

    System name:第8回病院改善提案プロジェクト

    Awarding organization:新潟大学医歯学総合病院

    牛木 隆志

      More details

    Authorship:Principal investigator 

    researchmap

  • メタボリックシンドローム組織慢性炎症における血球SOCS3の炎症抑制効果

    2017.4 - 2018.3

    System name:日本血液学会平成29年度研究助成

    Awarding organization:日本血液学会

    牛木 隆志

      More details

  • Glycosilation of glycosaminoglycan in bone marrow affect in hematopoiesis and GVHD after BM transplantation

    Grant number:16K09868

    2016.4 - 2020.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

    MASUKO MASAYOSHI

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    Chondroitin sulfate (CS), a glycosaminoglycan, is a major component of the extracellular matrix; however, it is not known whether CS has a physiological role in the hematopoiesis in BM. We analyzed the effects of CS on the BM microenvironment using knockout of N-acetylgalactosaminyltransferase-1, a key enzyme for CS biosynthesis that is important for regulating CS levels. HSPCs from T1KO mice showed significantly impaired repopulation in WT recipient mice upon serial transplantation. In contrast, the number of WT HSPCs repopulated in T1KO recipient mice was greater than that in WT recipient mice after serial transplantation, indicating that the T1KO BM niche supports repopulation of HSPCs better than the WT BM niche. RNA sequence analysis revealed that HSPCs in T1KO is associated with activation of the IFN-α/β signal and endoplasmic reticulum stress.

    researchmap

  • 造血幹細胞を用いた新規骨再生治療法の開発

    2016.4 - 2020.3

    System name:臨床研究サポート事業

    Awarding organization:新潟大学医歯学総合病院

    牛木 隆志

      More details

  • Molecular basis of novel bone regeneration pathway of cultured periosteum sheet

    Grant number:16K20534

    2016.4 - 2019.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

    Research category:Grant-in-Aid for Young Scientists (B)

    Awarding organization:Japan Society for the Promotion of Science

    Uematsu Koya, Ushiki Takashi

      More details

    Grant amount:\3900000 ( Direct Cost: \3000000 、 Indirect Cost:\900000 )

    In this study, differences in bone formation and cell accumulation and changes during bone regeneration were verified by comparing two types of culture conditions, a general-purpose medium and a medium for stem cells. As a result, it was suggested that periosteum sheet can mobilize many mesenchymal stem cells locally to the periosteum sheet depending on culture conditions. These mobilized cells accumulate through blood vessels and are localized around calcification, so they are likely to be a cell group strongly involved in ossification. It is necessary to add the analysis of the influence which mesenchymal stem cells exert on ossification from the data of these gene expression analysis from now on.
    There is a possibility that the efficiency of the periosteum sheet can be enhanced by developing an initial culture method to efficiently induce these cells.

    researchmap

  • 骨膜シートの骨髄細胞局所誘導能の増強は骨再生効果の飛躍的向上につながる

    Grant number:15H06228

    2015.8 - 2016.3

    System name:科学研究費助成事業 研究活動スタート支援

    Research category:研究活動スタート支援

    Awarding organization:日本学術振興会

    上松 晃也

      More details

    Grant amount:\1430000 ( Direct Cost: \1100000 、 Indirect Cost:\330000 )

    我々は骨膜細胞由来の培養人工骨:骨膜シートを用いた歯槽骨再生療法の研究を進めてきた。細胞移植による歯槽骨再生療法では、移植細胞が直接骨形成を行い骨となること念頭に長年研究がなされてきた。しかし、近年これとは反対に移植細胞が放出する増殖因子・サイトカインが元来からの骨治癒を補助・増強するという移植細胞の間接的な再生作用も報告されてきている。本研究では後者の間接的作用に焦点を当て、骨膜シートの放出する増殖因子・サイトカインが局所に骨髄細胞を誘導し骨再生を促進させるという仮説を検証する。これを通してより高い骨再生能を持つ骨膜シートの調製法を開発し、より予知性の高い治療法へのステップアップを目指す。
    <BR>
    平成27年度は、骨膜シート作製のための初期の段階である骨膜細胞の培養を実施。新規の培養法として培地の違いによる細胞の性質の変化を検証するとともに、これまでの骨膜シートを継代してさらに移植細胞を大量に調整するための疑似的な骨膜シートの開発・試作も行っている。
    また、調整した培養細胞を移植する実験動物として計画書に記載した骨髄細胞をGFP標識したマウスの作成も開始。現時点でキメリズム確認できており順調に進行している。

    researchmap

  • 自己免疫性肺胞蛋白症に対する酵母由来組換えGM-CSF吸入の多施設共同医師主導治験

    2015.5 - 2018.6

    Awarding organization:日本医療研究開発機構 難治性疾患実用化研究事業

    中田 光

      More details

  • Investigation on molecular mechanism for progression of pulmonary alveolar proteinosis by next generation sequencing.

    Grant number:15H04829

    2015.4 - 2018.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

    Research category:Grant-in-Aid for Scientific Research (B)

    Awarding organization:Japan Society for the Promotion of Science

    Nakata Koh

      More details

    Grant type:Competitive

    Grant amount:\17940000 ( Direct Cost: \13800000 、 Indirect Cost:\4140000 )

    Autoimmune pulmonary alveolar proteinosis is caused by GM-CSF autoantibodies. We investigated the mechanism for polyclonality of the autoantibody and assessed the process for the clonal selection and expansion of autoreactive B cells against GM-CSF. We first generated bias-free full-length cDNA library from the circulating GM-CSF autoreactive B cells in ten patients, then amplified Ig specific PCR amplicons, and performed the deep sequencing. Most clones belonged to each one unique B cell lineage in one-to-one relationship. Somatic hyper mutation accounted for only up to 0.6% of the total. Thus, polyclonality of Igs in GM-CSF autoreactive B cell clones was mostly dependent on the variability of naive B cell clones.

    researchmap

  • SOCS1/3欠失マウスで増加する特異なT細胞分画が移植片対宿主病に及ぼす役割

    2015.4 - 2018.3

    System name:科学研究費助成事業 若手研究(B)

    Awarding organization:日本学術振興会

    牛木 隆志

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 血液型抗原減弱例の背景解析とその臨床的対処法の検討

    2014.4 - 2017.3

    System name:臨床研究サポート事業

    Awarding organization:新潟大学医歯学総合病院

    牛木 隆志

      More details

  • 輸血の無駄をなくす診療科横断的プロジェクト

    2014.4 - 2015.3

    System name:第5回病院改善提案プロジェクト

    Awarding organization:新潟大学医歯学総合病院

    牛木 隆志

      More details

    Authorship:Principal investigator 

    researchmap

▶ display all

 

Teaching Experience (researchmap)

  • Comprehensive health sciences

    2024

     More details

  • Practice of Laboratory Immunology and Hematology

    2023

     More details

  • Graduation Thesis

    2023

     More details

  • Master’s Research for Health Sciences (Sciences of Medical Technology)

    2023

     More details

  • Clinical Aspect of Laboratory Human Sciences

    2023

     More details

  • Laboratory Immunology and Hematology

    2023

     More details

  • Laboratory Hematology and Oncology

    2023

     More details

  • Doctor’s Research for Health Sciences (Sciences of Medical Technology)

    2023

     More details

  • Practice of Laboratory Hematology and Oncology

    2023

     More details

  • Study Skills

    2022

     More details

  • Medical English

    2022

     More details

  • Pathophysiology

    2022

     More details

  • Prevention and Treatment of Disease

    2022

     More details

  • Physical Assessment

    2022

     More details

  • Clinical Pharmacology

    2022

     More details

  • Hematology II

    2022

     More details

  • Clinical Practice of Medical Technology

    2022

     More details

  • Genomic Laboratory Science

    2022

     More details

  • Medical Treatments

    2022

     More details

  • Pathophysiology of the Diseases II

    2022

     More details

  • Pathophysiology

    2022

     More details

  • Acurracy Management of Laboratory Medicine

    2022

     More details

  • Hematology I

    2022

     More details

  • Structure and Function of Human Body Ⅱ

    2022

     More details

  • Pathogenesis and Treatment of Disease Ⅰ

    2022

     More details

  • Hematology Laboratory

    2022

     More details

  • Diseases and the Associated Laboratory Medicine

    2022

     More details

  • 液性調節病態学

    2021
    -
    2022
    Institution name:新潟大学大学院医歯学総合研究科

     More details

  • 再生医療学

    2018
    Institution name:新潟大学医学部医学科

     More details

  • 臓器別講義コース(1)「血液系」

    2014
    -
    2022
    Institution name:新潟大学医学部医学科

     More details

  • 全身管理学「輸血学」

    2014
    -
    2022
    Institution name:新潟大学歯学部歯学科

     More details

  • 統合臨床医学「外科的手技・処置の基礎知識」

    2014
    -
    2022
    Institution name:新潟大学医学部医学科

     More details

  • 輸血・細胞治療学

    2013
    Institution name:新潟大学医学部医学科

     More details

  • 臨床実習入門ローテーション実習「輸血とクロスマッチ」

    2013
    -
    2017
    Institution name:新潟大学医学部医学科

     More details

  • 血液学

    2009
    Institution name:新潟医療技術専門学校

     More details

▶ display all

Teaching Experience

  • 卒業研究

    2023
    Institution name:新潟大学

  • 免疫・血液病態検査科学特講演習

    2023
    Institution name:新潟大学

  • 疾病の成因と治療

    2023
    Institution name:新潟大学

  • 血液・腫瘍検査学実習

    2023
    Institution name:新潟大学

  • 免疫・血液病態検査科学特講

    2023
    Institution name:新潟大学

  • 血液・腫瘍検査学特論

    2023
    Institution name:新潟大学

  • 医療英語(検査)

    2023
    Institution name:新潟大学

  • 保健学特別研究(検査技術科学)

    2023
    Institution name:新潟大学

  • 医学検査管理総論

    2022
    Institution name:新潟大学

  • 血液検査科学実習

    2022
    Institution name:新潟大学

  • 血液学II

    2022
    Institution name:新潟大学

  • 血液学I

    2022
    Institution name:新潟大学

  • 病気の成り立ちII

    2022
    Institution name:新潟大学

  • 臨床検査実習

    2022
    Institution name:新潟大学

  • 臨床生体情報検査科学論

    2022
    Institution name:新潟大学

  • 病態論

    2022
    Institution name:新潟大学

  • 臨床薬理学

    2022
    Institution name:新潟大学

  • 病態生理学

    2022
    Institution name:新潟大学

  • ゲノム検査科学

    2022
    Institution name:新潟大学

  • 疾病の成因と治療I

    2022
    Institution name:新潟大学

  • スタディスキルズ (検査)

    2022
    Institution name:新潟大学

  • 治療法概説

    2022
    Institution name:新潟大学

  • フィジカルアセスメント

    2022
    Institution name:新潟大学

  • 疾病の予防と治療

    2022
    Institution name:新潟大学

  • 人体の構造と機能II

    2022
    Institution name:新潟大学

  • 疾患と臨床検査

    2022
    Institution name:新潟大学

▶ display all

 

Social Activities

  • 新潟県血液対策推進協議会

    Role(s): Advisor

    2014

     More details

  • 新潟県合同輸血療法委員会

    Role(s): Organizing member

    2014

     More details

Academic Activities

  • 第72回 日本輸血・細胞治療学会学術総会

    Role(s): Panel moderator, session chair, etc.

    日本輸血・細胞治療学会  2024.5

     More details

    Type:Academic society, research group, etc. 

    researchmap

  • 第23回 日本再生医療学会総会

    Role(s): Panel moderator, session chair, etc., Peer review

    日本再生医療学会  2024.3

     More details

    Type:Academic society, research group, etc. 

    researchmap

  • 第72回 日本輸血・細胞治療学会学術総会 プログラム委員会

    Role(s): Review, evaluation, Peer review

    日本輸血・細胞治療学会  2023.12

     More details

    Type:Academic society, research group, etc. 

    researchmap

  • Special Issue Editors "Recent Progress in Regenerative Therapy Using Blood-Derived Biomaterials"

    Role(s): Planning, management, etc.

    International journal of molecular sciences  2023.7 - 2024.6

     More details

    Type:Scientific advice/Review 

    researchmap

  • 新潟大学 人を対象とする研究等倫理審査委員会 委員

    Role(s): Review, evaluation

    新潟大学  2020.4 - 2024.3

     More details

  • 第65回 日本輸血・細胞治療学会学術総会

    Role(s): Panel moderator, session chair, etc.

    日本輸血・細胞治療学会  2017.6

     More details

  • 第64回 日本輸血・細胞治療学会学術総会

    Role(s): Panel moderator, session chair, etc., Review, evaluation

    日本輸血・細胞治療学会  2016.4

     More details

  • 血液製剤使用適正化方策調査研究事業 調査班長

    Role(s): Planning/Implementing academic research

    厚生労働省、新潟県合同輸血療法委員会  2016 - 2019

     More details

    Type:Academic research 

    researchmap

  • 新潟大学 認定再生医療等委員会 委員

    Role(s): Review, evaluation

    新潟大学  2015 - 2019

     More details

  • 新潟輸血研究会 副会長・幹事

    Role(s): Planning, management, etc.

    2014

     More details

    Type:Academic society, research group, etc. 

    researchmap

  • 新潟大学 セル・プロセッシングセンター 製造管理責任者

    Role(s): Planning, management, etc.

    新潟大学医歯学総合病院  2014

     More details

  • 新潟県輸血フォーラム

    Role(s): Planning, management, etc., Panel moderator, session chair, etc.

    新潟県、新潟輸血研究会  2013

     More details

  • 新潟大学医歯学総合病院 遺伝子治療臨床研究に関する倫理委員会 委員

    Role(s): Review, evaluation

    新潟大学医歯学総合病院  2013

     More details

▶ display all